var title_f19_17_19728="Saber sheath ratio";
var content_f19_17_19728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic representation of saber sheat trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This deformity is characterized by narrowing of the trachea in the coronal plane (c) combined with widening in the sagittal plane (s). A ratio of coronal to sagittal diameter &le;0.6 is suggestive of this diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19728=[""].join("\n");
var outline_f19_17_19728=null;
var title_f19_17_19729="Anatomy of rectal prolapse";
var content_f19_17_19729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of rectal prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: partial prolapse; B: complete prolapse; C: prolapsed intussusception.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19729=[""].join("\n");
var outline_f19_17_19729=null;
var title_f19_17_19730="Exam for gynecomastia";
var content_f19_17_19730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Examination for gynecomastia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Physical examination method to distinguish gynecomastia, due to enlargement of the glandular tissue, from pseudogynecomastia, due to excessive adipose tissue. The thumb and forefinger are placed on opposite sides of the breast and slowly brought together towards the areolar-nipple complex. Gynecomastia is appreciated as a concentric, rubbery-to-firm disk of tissue, often mobile, located directly beneath the areolar area. Pseudogynecomastia presents no discrete mass, and other masses due to disorders such as cancer tend to be eccentrically positioned (insert).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Braunstein GD. Gynecomastia. N Engl J Med 2007; 357:1229.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19730=[""].join("\n");
var outline_f19_17_19730=null;
var title_f19_17_19731="Malrotation at surgery";
var content_f19_17_19731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malrotation at surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With malrotation, Ladd's bands cross the duodenum, causing extrinsic obstruction. Here the Ladd's bands have been lifted up to expose the duodenum underneath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary L Brandt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19731=[""].join("\n");
var outline_f19_17_19731=null;
var title_f19_17_19732="Tazarotene: Drug information";
var content_f19_17_19732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tazarotene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/32/26116?source=see_link\">",
"    see \"Tazarotene: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/60/3012?source=see_link\">",
"    see \"Tazarotene: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avage&reg;;",
"     </li>",
"     <li>",
"      Tazorac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tazorac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F224862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Keratolytic Agent;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In patients experiencing excessive pruritus, burning, skin redness, or peeling, discontinue until integrity of the skin is restored, or reduce dosing to an interval the patient is able to tolerate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Topical: Tazorac&reg; cream/gel 0.1%: Apply a thin film (2 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     ) to affected area once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines:",
"     </b>",
"     Topical: Avage&trade;: Apply a pea-sized amount once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Topical: Tazorac&reg; cream/gel: Initial: 0.05%: Apply once daily to psoriatic lesions using enough (2 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     ) to cover only the lesion with a thin film. May increase strength to 0.1% if tolerated and necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F224855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/60/3012?source=see_link\">",
"      see \"Tazarotene: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In patients experiencing excessive pruritus, burning, skin redness, or peeling, discontinue until integrity of the skin is restored, or reduce dosing to an interval the patient is able to tolerate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Children &ge;12 years: Topical: Tazorac&reg; gel: Initial: 0.05%: Apply once daily to psoriatic lesions using enough (2 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     ) to cover only the lesion with a thin film to no more than 20% of body surface area. May increase strength to 0.1% if tolerated and necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines:",
"     </b>",
"     Children &ge;17 years: Topical: Avage&trade;: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F224844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avage&reg;: 0.1% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazorac&reg;: 0.05% (30 g, 60 g); 0.1% (30 g, 60 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazorac&reg;: 0.05% (30 g, 100 g); 0.1% (30 g, 100 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F224823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not apply to eczematous or sunburned skin; avoid eyes and mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acne: Apply in evening after gently cleansing and drying face; apply enough to cover entire affected area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines: Apply to clean dry face at bedtime; lightly cover entire face including eyelids if desired. Emollients or moisturizers may be applied before or after; if applied before tazarotene, ensure cream or lotion has absorbed into the skin and has dried completely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Psoriasis: Apply in evening. If a bath or shower is taken prior to application, dry the skin before applying. If emollients are used, apply them at least 1 hour prior to application. Unaffected skin may be more susceptible to irritation, avoid application to these areas.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of facial acne vulgaris; topical treatment of stable plaque psoriasis; mitigation (palliation) of facial skin wrinkling, facial mottled hyper-/hypopigmentation, and benign facial lentigines",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentage of incidence varies with formulation and/or strength:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Burning/stinging, desquamation, dry skin, erythema, irritation, pruritus, skin pain, worsening of psoriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cheilitis, contact dermatitis, discoloration, eczema, fissuring,  inflammation, localized bleeding, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Frequency not defined: Dermatologic: Photosensitization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Blistering",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tazarotene, other retinoids or vitamin A derivatives (isotretinoin, tretinoin, etretinate), or any component of the formulation; use in women of childbearing potential who are unable to comply with birth control requirements; pregnancy (negative pregnancy test required)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity; exposure to sunlight should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized (including use of sunscreens/protective clothing). Risk may be increased by concurrent therapy with known photosensitizers (thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Skin irritation: Treatment can increase skin sensitivity to weather extremes of wind or cold. Also, concomitant topical medications (eg, medicated or abrasive soaps, cleansers, or cosmetics with a strong drying effect) should be used with caution due to increased skin irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women of childbearing potential: Must use adequate contraceptive measures because of potential teratogenicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gel: Safety and efficacy of gel applied over &gt;20% of BSA have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with eyes, eyelids, and mouth. Not for use on eczematous, broken, or sunburned skin; not for treatment of lentigo maligna. Avoid application over extensive areas.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm if administered to a pregnant woman. A negative pregnancy test should be obtained within 2 weeks prior to treatment; treatment should begin during a normal menstrual period.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F224846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17916858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tazarotene is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tazarotene to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F224827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Avage External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (30 g): $282.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tazorac External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $265.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (30 g): $282.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Tazorac External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $265.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (30 g): $282.43",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F224818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disease severity in plaque psoriasis during therapy (reduction in erythema, scaling, induration); pregnancy test prior to treatment of female patients",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aguder (CN);",
"     </li>",
"     <li>",
"      Avage (NZ, SG);",
"     </li>",
"     <li>",
"      Ful Lee (TW);",
"     </li>",
"     <li>",
"      Le Wei (CL);",
"     </li>",
"     <li>",
"      Pzoret (CO);",
"     </li>",
"     <li>",
"      Que Wei (CL);",
"     </li>",
"     <li>",
"      Rantric (CO);",
"     </li>",
"     <li>",
"      Sumaytene (TW);",
"     </li>",
"     <li>",
"      Suretin (CH, IT, MX);",
"     </li>",
"     <li>",
"      Tarac (TW);",
"     </li>",
"     <li>",
"      Tazoderm Forte (IN);",
"     </li>",
"     <li>",
"      Tazorac (CZ);",
"     </li>",
"     <li>",
"      Tazoten (TW);",
"     </li>",
"     <li>",
"      Tazret (PH);",
"     </li>",
"     <li>",
"      Zorac (AT, AU, BE, BG, BR, DE, ES, FR, GB, GR, IE, IL, IT, NZ, PL, SE);",
"     </li>",
"     <li>",
"      Zorac Gel (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic, acetylenic retinoid which modulates differentiation and proliferation of epithelial tissue and exerts some degree of anti-inflammatory and immunological activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Therapeutic: Psoriasis: Effects have been observed for up to 3 months after a 3-month course of topical treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal following cutaneous application (&le;6% of dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Retained in skin for prolonged periods after topical application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug, rapidly metabolized via esterases to an active metabolite (tazarotenic acid) following topical application and systemic absorption; tazarotenic acid undergoes further hepatic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9665 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19732=[""].join("\n");
var outline_f19_17_19732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224841\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224862\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224843\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224855\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224844\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224820\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224805\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224823\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224822\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224860\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224826\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224809\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300105\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224814\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224816\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224828\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224846\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916858\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224827\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224818\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224829\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224808\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224825\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/32/26116?source=related_link\">",
"      Tazarotene: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/60/3012?source=related_link\">",
"      Tazarotene: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_17_19733="Confounding in Mendelian randomization";
var content_f19_17_19733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Confounding in Mendelian randomization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 672px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Confounding by linkage disequilibrium occurs when loci in close proximity to the risk allele are predictors of the outcome.",
"    <br>",
"     (B) Confounding by population stratification occurs when ethnicity (or genetic ancestry) is associated with both the risk allele and the outcome.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19733=[""].join("\n");
var outline_f19_17_19733=null;
var title_f19_17_19734="Postinfectious GN Light Low";
var content_f19_17_19734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postinfectious glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light micrograph showing diffuse, proliferative glomerulonephritis as may be seen in postinfectious glomerulonephritis. The glomeruli are so hypercellular (arrows) that open capillary lumens cannot be seen and the glomeruli may be hard to distinguish from the surrounding interstitium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19734=[""].join("\n");
var outline_f19_17_19734=null;
var title_f19_17_19735="Communication of prognosis in palliative care";
var content_f19_17_19735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Communication of prognosis in palliative care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19735/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19735/contributors\">",
"     Alexander Smith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19735/contributors\">",
"     Susan D Block, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19735/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/17/19735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11773416\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis is the science of estimating the likelihood of an outcome (eg, death, disability) due to a medical condition (eg, cancer, heart failure, late-life disability). Prognosis may address many outcomes that patients care deeply about, such as the likelihood of losing the ability to care for oneself independently, of treatment leading to a cure, or of developing a debilitating condition such as dementia. This topic will focus primarily on communicating prognosis for life expectancy or survival.",
"   </p>",
"   <p>",
"    Nicholas Christakis has described the &ldquo;ellipsis of prognosis&rdquo; in medical teaching [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the time of Osler, textbooks focused equally on diagnosis, treatment, and prognosis. Prognosis now makes up a scant one to two lines of most medical textbooks, and medical students and residents receive little training in how to estimate or communicate prognosis. Additionally, patterns of current practice suggest that prognosis is not routinely incorporated into clinical decision-making.",
"   </p>",
"   <p>",
"    The growing palliative care movement is refocusing attention on the importance of prognosis in decision making for seriously ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Prognosis reaches paramount importance at the end of life, when the risks and burdens of treatments and their alternatives must clearly be weighed in view of the patient&rsquo;s life expectancy and personal goals.",
"   </p>",
"   <p>",
"    This topic will discuss the science of estimating prognosis and focus on how best to communicate this information to patients and family members. Indicators of prognosis for specific medical conditions are available in disease-specific topics in UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11773282\">",
"    <span class=\"h1\">",
"     THE IMPORTANCE OF PROGNOSIS IN CLINICAL PRACTICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks and benefits of any test or treatment must be considered in light of the patient&rsquo;s expected prognosis. Thus, understanding and communicating prognosis is an important element of any clinical decision-making. Determination of eligibility for hospice, where clinicians must certify a prognosis of six months or less should the disease run its usual course, is the paradigmatic example of the need to be able to determine prognosis. The importance of understanding prognosis for multiple other clinical decisions is shown in a table, organized by shortest prognosis to longest (",
"    <a class=\"graphic graphic_table graphicRef87445 \" href=\"UTD.htm?0/17/286\">",
"     table 1",
"    </a>",
"    ). The table includes only those decisions where a guideline, professional organization, or recognized experts have recommended a specific prognostic cutoff; these represent only a subset of decisions that are routinely made in light of prognosis.",
"   </p>",
"   <p>",
"    Most often, there are no specific guidelines addressing clinical decisions that must be made for patients with serious illness. Such common decisions include initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for pain without monitoring QTc interval [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/5\">",
"     5",
"    </a>",
"    ], discontinuation of anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/6\">",
"     6",
"    </a>",
"    ], and deactivation of implantable cardioverter-defibrillators [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/7\">",
"     7",
"    </a>",
"    ]. Prognosis is clearly vital to each of these decisions, despite the lack of explicit guidelines on which to base these decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30374933\">",
"    <span class=\"h2\">",
"     Patient-important factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table (",
"    <a class=\"graphic graphic_table graphicRef87445 \" href=\"UTD.htm?0/17/286\">",
"     table 1",
"    </a>",
"    ) considers the medical rationale for including prognosis in medical decision making. Patients frequently cite non-medical reasons at least as strongly as medical reasons for wanting to know prognosis. In one study involving 60 African American, Latino, Chinese, and white disabled older adults, 75 percent stated they would want to know if their doctor thought they had less than one year to live [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/8\">",
"     8",
"    </a>",
"    ]. Reasons given included having time to put their spiritual affairs in order, to say &ldquo;goodbye&rdquo;, and to prepare financially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11773289\">",
"    <span class=\"h1\">",
"     RATIONALE FOR DISCUSSING PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Western medicine has slowly transitioned from a paternalistic model to a model based on informed shared decision making. The doctrine of informed consent obligates clinicians to provide patients with information such as prognosis, that is critical to their decision to accept or refuse treatments. Going beyond informed consent, the shared decision making model promotes a more bidirectional exchange of information so that patients and clinicians can deliberate collaboratively about the best courses of action [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognostic information is often integral to the health decisions and life choices patients are making in their last years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients who have a good understanding of their prognosis tend to make different decisions than those who are not aware, including less use of aggressive life-sustaining treatments at the end of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Too often, however, patients are making decisions with little prognostic awareness. As an example, in a study of 1193 patients with metastatic lung and colorectal cancer, 69 percent of those with lung cancer and 81 percent of those with colorectal cancer did not report understanding that chemotherapy was not at all likely to cure their cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians may be reluctant to discuss prognostic information because they are concerned it will negatively affect the patient-doctor relationship, or the patient&rsquo;s psychological state. Clinicians frequently articulate the concern that discussing prognosis will &ldquo;take away hope.&rdquo; Indeed, in the study of patients with metastatic lung and colorectal cancer, understanding that chemotherapy was not curative was associated with lower patient ratings of clinician satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/14\">",
"     14",
"    </a>",
"    ]. In other studies, however, discussion of prognosis led to greater patient satisfaction, lower anxiety and depression, and less likelihood of using alternative therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Patient satisfaction may be the wrong metric for measuring the outcomes of these conversations, however. A potentially more appropriate measure, as yet untested, might be to ask patients and families later in their illness trajectory if having the discussion about prognosis helped them to prepare for the end of life.",
"   </p>",
"   <p>",
"    Evidence is mounting that inadequate preparation for death leads to poor bereavement outcomes, including depression, a sense of regret, and complicated grief [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ]. Thus, the evidence suggests that prognosis discussions are likely to lead to not worse, but better psychological outcomes for patients and their families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11773296\">",
"    <span class=\"h1\">",
"     THE SCIENCE OF ESTIMATING PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major practical barrier to discussing prognosis is the lack of certainty in prognostic information. With increasing availability of data from national surveys and clinical trials, the science of estimating prognosis has made remarkable progress. Nonetheless, some argue that available prognostic tools lack the accuracy, generalizability, and usability for routine clinical use.",
"   </p>",
"   <p>",
"    Although prognostic information from a prognostic tool is not perfectly accurate, clinicians&rsquo; own empiric estimates of prognosis are likely to be far less accurate. Studies suggest that clinicians consistently overestimate survival. In a systematic review of clinicians&rsquo; predications of survival estimates, the mean predicted survival among the eight evaluated studies was 42 days, whereas the actual survival was 29 days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of information from prognostic tools and clinical judgment results in a better prognostic estimate than either alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Available prognostic tools for use in clinical decision making for older adults are available through",
"    <a class=\"external\" href=\"file://www.eprognosis.org/\">",
"     eprognosis.org",
"    </a>",
"    . Prognostic calculators for patients with specific conditions are available in UpToDate as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced cancer: (See",
"      <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link\">",
"       \"Survival estimates in advanced terminal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advanced liver disease: (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"       \"Model for End-stage Liver Disease (MELD)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coronary heart disease: (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"       \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link\">",
"       \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure: (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"       \"Prognosis of heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ICU mortality: (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=see_link\">",
"       \"Predictive scoring systems in the intensive care unit\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatitis: (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"       \"Predicting the severity of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several factors must be weighed in the decision to use a given prognostic tool in clinical decision making. Chief among these are the extent to which a given tool was tested in a population of patients that resembles the clinical setting at hand, the extent to which the index has been tested and found to be accurate across geographic regions and time, and its accuracy when applied to patients of varying illness severity.",
"   </p>",
"   <p>",
"    In addition to the calculators above, two systematic reviews may provide guidance for identifying patients with end stage illness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The systematic reviews, based on a literature search of over 1000 articles, have identified patient presentations associated with median survival of six months or less for patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/24\">",
"     24",
"    </a>",
"    ] or six noncancer illnesses (heart failure, chronic obstructive pulmonary disease, dementia, geriatric failure to thrive, cirrhosis, and end stage renal failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/23\">",
"     23",
"    </a>",
"    ]. These sample presentations may identify patients in whom aggressive treatment is unlikely to prolong survival and for whom hospice services may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11773303\">",
"    <span class=\"h1\">",
"     ASSESSING PATIENT AND/OR FAMILY READINESS TO DISCUSS PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of patients with serious illness demonstrate that a majority of adults would want their clinician to discuss prognostic information. In a study of 60 white, Chinese, Latino, and African American disabled older adults, 75 percent would want their clinician to talk to them about prognosis if they had less than one year to live, and results were similar across ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/8\">",
"     8",
"    </a>",
"    ]. In another study of 214 community-dwelling adults with disability and advanced cancer, chronic obstructive pulmonary disease, or congestive heart failure, over half of subjects wanted to discuss prognosis with their doctor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/25\">",
"     25",
"    </a>",
"    ]. Variation by age and gender was not found in these studies, though other studies in patients with cancer suggest that older patients and men are more reluctant to discuss prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cultures, there is a higher prevalence of wanting to avoid prognostic information or to prefer that family be told the information [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Clinicians should be aware that variation within cultures is likely as great as variation between cultures, however, and avoid stereotyping based on phenotypic characteristics such as age, gender, or",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a patient&rsquo;s family expresses a strong preference against sharing prognostic information with the patient, clinicians should first explore the family&rsquo;s concerns about sharing the information, as family members may have important information. The clinician should explain that the decision about whether to receive prognostic information belongs to the patient. The family should be invited to join the discussion when the clinician asks the patient whether",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    wants this information. The clinician should explain in advance that, if the patient requests prognostic information, it will be shared, and if the patient prefers not to receive the information, the clinician will not provide it. Usually, this approach is acceptable to the family, who then hears directly from the patient about",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    information preferences, reducing conflict and disagreement.",
"   </p>",
"   <p>",
"    Patients who prefer that prognosis not be discussed with their health providers cite several reasons for this preference: concern that discussing prognosis is too emotionally difficult, that the information would not be useful, or that they may not believe that doctors can estimate prognosis accurately [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should offer to discuss prognostic information, but respect the preferences of patients who are not willing or prepared to discuss prognosis. For example, clinicians can say:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;In order to make this decision, I think it might be helpful if we talked about how much time you might have left to live. What are your thoughts on discussing this information?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the need to discuss prognosis is critical to decision making, but patients are reluctant to discuss the information, clinicians should obtain an understanding of the reasons for reluctance. Understanding these reasons may provide important clues about how to approach this difficult topic in a way that is acceptable to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/33\">",
"     33",
"    </a>",
"    ]. For example, clinicians might say:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Please help me to understand why you would prefer not to discuss this information, so that I have a better sense of how to approach these difficult topics with you in the future&rdquo;.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, when the decision is particularly urgent, prognosis might be brought into the conversation hypothetically, to obtain a sense of the patient&rsquo;s values and goals. For example, the clinician might say:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;If you knew that time was short for you, and I&rsquo;m not saying that it is, what would be important to you?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, patients may cede decision making to a caregiver who is more willing to discuss prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11773310\">",
"    <span class=\"h1\">",
"     DISCUSSING PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30374957\">",
"    <span class=\"h2\">",
"     When to discuss prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, prognosis discussions should take place when the patient is not ill and is therefore better able to process and understand information, and is not overwhelmed by anxiety due to an acute medical event. Unfortunately, these discussions too often are initiated after acute deteriorations or progression of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients may be overwhelmed with anxiety and there is evidence to suggest that patients tend to opt for highly aggressive therapies when they are anxious or experiencing strong emotions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A study of 1231 patients with stage IV lung or colorectal cancer found that patients who have end-of-life discussions with their physician prior to the last month of life were less likely to receive highly aggressive care, such as hospitalizations and chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30374967\">",
"    <span class=\"h2\">",
"     How to discuss prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any discussion in which clinicians need to share bad news with patients, clinicians need to prepare in advance for the discussion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/38\">",
"     38",
"    </a>",
"    ]. This includes making sure the discussion will take place in a private setting without disturbances such as frequent pager calls. Patients should have the support of a caregiver, if desired, to provide support and help process and interpret the prognostic information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30374926\">",
"    <span class=\"h3\">",
"     Stepwise strategy for discussion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stepwise strategy for such discussions is presented as a general guide, recognizing that clinicians will adapt this approach to the case at hand and their own communication style:",
"   </p>",
"   <p>",
"    <strong>",
"     Step one:",
"    </strong>",
"    Place the prognosis discussion in context. A discussion of prognosis rarely occurs in a vacuum, and is almost always tied to treatment decisions. Clinician should explain that an understanding of prognosis can be helpful, or even critical, to making informed health care decisions and life choices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Step two",
"    </strong>",
"    : Ask patients and families about their own understanding of prognosis. This can be accomplished with a question such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;So that I can understand where we are starting from, I wonder if you have some general sense of how much time you might have, and how you came up with that information?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This step is often overlooked. However, studies of surrogates of critically ill patients suggest that families rarely rely on clinicians alone for prognostic information. In one study of 179 surrogates of critically ill patients, less than 2 percent relied exclusively on clinicians for prognostic information [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/39\">",
"     39",
"    </a>",
"    ]. Other sources of information used by patients and families include their own observations about the trajectory of illness, the patient&rsquo;s will to live, their sense of optimism, and faith. Being aware of the understanding of the patient and family",
"    <strong>",
"    </strong>",
"    about prognosis, and the reasons for their perception, is a critical starting point for clinicians, who may later wonder why their prognostic estimates were &ldquo;not believed.&rdquo;",
"   </p>",
"   <p>",
"    <strong>",
"     Step three",
"    </strong>",
"    : Negotiate the content of the prognostic discussion with patients and families. Preferences for receiving prognostic information vary, with some patients preferring qualitative estimates, others quantitative statistics, or best and worst case scenarios. Some may prefer to discuss the numbers, while other patients may prefer to receive information visually. A number of decision aids have been developed for these purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/40\">",
"     40",
"    </a>",
"    ]. The website",
"    <a class=\"external\" href=\"file://eprognosis.org/\">",
"     eprognosis.org",
"    </a>",
"    presents a number of these calculators.",
"   </p>",
"   <p>",
"    <strong>",
"     Step four",
"    </strong>",
"    : Deliver the prognostic information. When delivering the prognostic information, clinicians should use language that emphasizes the range of possible outcomes. Ranges are important because of the inherent uncertainty in any prognostic information. For example, one might give a prognosis for life expectancy in hours to days, days to weeks, weeks to months, months on one hand, or months to a year at most. Clinicians can acknowledge that dealing with uncertainty may be difficult psychologically for patients and families, as in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;I wish the information were more certain. I understand that you would like more certain information. But that certainty does not exist. How can I help you to cope with that uncertainty?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients may find it helpful to refocus on the present, rather than dwell on the uncertainty of the future. When time is likely to be short, helping patients focus on personal goals can be an antidote to strong feelings that are often generated by an awareness of limited time. &nbsp;",
"   </p>",
"   <p>",
"    Clinicians should be mindful that the framing of the prognostic information may influence the decisions patients make. For example, in the case of chemotherapy for cancer, patients are more likely to choose treatment if the risks are presented as likelihood of cure rather than of death. For this information, clinicians should consider presenting risk information in both positive and negative frames. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Out of 100 people similar to you, 35 will die within five years and 65 will survive.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other patients may prefer to receive prognostic information qualitatively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/40\">",
"     40",
"    </a>",
"    ]. In the example below, qualitative prognostic information is tied in with a recommendation for care (step 6), illustrating how these steps can be adapted to the clinical situation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;I worry that, because your cancer has progressed despite all the chemotherapy we have to offer, that time may be short for you. At this time, I suggest we focus on getting you enrolled in hospice now so that we can get you out of the hospital and let you be with your family.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Step five",
"    </strong>",
"    : Respond to emotion. Attending to the affective response to prognostic information is of critical importance. Clinicians need to be sensitive to patient and family distress at hearing the prognosis. This can be accomplished by providing supportive statements and questions. However, it is important to avoid providing false reassurance to the patient in response to intense distress. One useful mnemonic for attending to affect are the NURSE statements and questions, as described in a table (",
"    <a class=\"graphic graphic_table graphicRef75046 \" href=\"UTD.htm?13/3/13371\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19735/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Step six:",
"    </strong>",
"    Agree on a plan for the next steps. This may be a follow-up appointment to discuss treatment options in light of the prognostic information, additional testing that may help clarify the prognosis, or a supportive visit to provide additional time to process the emotional content of the prognosis and its implications. For many patients, &ldquo;structure is the antidote to despair,&rdquo; and they rely on a sense of a plan for the future to help cope with unwanted news.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11773317\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prognostic information is a critical component of informed shared decision making. The risks and benefits of any test or treatment must be considered in light of the patient&rsquo;s expected prognosis. Prognosis has bearing both on medical decisions as well as other factors important to patients, including addressing spiritual, financial, and interpersonal issues. (See",
"      <a class=\"local\" href=\"#H11773282\">",
"       'The importance of prognosis in clinical practice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have a good understanding of their prognosis tend to make different medical decisions than those who are not aware. A clinician&rsquo;s fear of discussing prognosis because it may provoke negative feelings is not an adequate reason for avoiding discussions of unwelcome news. Evidence is mounting that inadequate preparation for death leads to poor bereavement outcomes, including depression, a sense of regret, and complicated grief. (See",
"      <a class=\"local\" href=\"#H11773289\">",
"       'Rationale for discussing prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although prognostic information from a prognostic tool is not perfectly accurate, clinicians&rsquo; own empiric estimates of prognosis are likely to be far less accurate. The combination of information from prognostic tools and clinical judgment results in a better prognostic estimate than either alone. (See",
"      <a class=\"local\" href=\"#H11773296\">",
"       'The science of estimating prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A majority of patients with serious illness would want their clinician to discuss prognostic information. Such information should be offered to patients and never forced upon them. (See",
"      <a class=\"local\" href=\"#H11773303\">",
"       'Assessing patient and/or family readiness to discuss prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discussions of prognosis should proceed in a stepwise manner that reflects the science of how patients and families perceive and respond to prognostic information. Above all, prognosis discussions must proceed with an intense sensitivity to the emotional reactions of patients and families. (See",
"      <a class=\"local\" href=\"#H11773310\">",
"       'Discussing prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/1\">",
"      Christakis NA. The ellipsis of prognosis in modern medical thought. Soc Sci Med 1997; 44:301.",
"     </a>",
"    </li>",
"    <li>",
"     Christakis NA. Death Foretold: Prophecy and Prognosis in Medical Care, University of Chicago Press, Chicago 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/3\">",
"      Lamont EB, Christakis NA. Complexities in prognostication in advanced cancer: \"to help them live their lives the way they want to\". JAMA 2003; 290:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/4\">",
"      Yourman LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older adults: a systematic review. JAMA 2012; 307:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/5\">",
"      Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/6\">",
"      Holmes HM, Bain KT, Zalpour A, et al. Predictors of anticoagulation in hospice patients with lung cancer. Cancer 2010; 116:4817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/7\">",
"      Lampert R, Hayes DL, Annas GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/8\">",
"      Ahalt C, Walter LC, Yourman L, et al. \"Knowing is better\": preferences of diverse older adults for discussing prognosis. J Gen Intern Med 2012; 27:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/9\">",
"      Moulton B, King JS. Aligning ethics with medical decision-making: the quest for informed patient choice. J Law Med Ethics 2010; 38:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/10\">",
"      King JS, Moulton BW. Rethinking informed consent: the case for shared medical decision-making. Am J Law Med 2006; 32:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/11\">",
"      Smith AK, Williams BA, Lo B. Discussing overall prognosis with the very elderly. N Engl J Med 2011; 365:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/12\">",
"      Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998; 279:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/13\">",
"      Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008; 300:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/14\">",
"      Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/15\">",
"      Chochinov HM, Tataryn DJ, Wilson KG, et al. Prognostic awareness and the terminally ill. Psychosomatics 2000; 41:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/16\">",
"      Pruyn JF, Rijckman RM, van Brunschot CJ, van den Borne HW. Cancer patients' personality characteristics, physician-patient communication and adoption of the Moerman diet. Soc Sci Med 1985; 20:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/17\">",
"      Barry LC, Prigerson HG. Perspectives on preparedness for a death among bereaved persons. Conn Med 2002; 66:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/18\">",
"      Hebert RS, Prigerson HG, Schulz R, Arnold RM. Preparing caregivers for the death of a loved one: a theoretical framework and suggestions for future research. J Palliat Med 2006; 9:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/19\">",
"      Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003; 327:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/20\">",
"      Knaus WA, Harrell FE Jr, Lynn J, et al. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med 1995; 122:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/21\">",
"      Teno JM, Harrell FE Jr, Knaus W, et al. Prediction of survival for older hospitalized patients: the HELP survival model. Hospitalized Elderly Longitudinal Project. J Am Geriatr Soc 2000; 48:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/22\">",
"      Charlson ME, Hollenberg JP, Hou J, et al. Realizing the potential of clinical judgment: a real-time strategy for predicting outcomes and cost for medical inpatients. Am J Med 2000; 109:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/23\">",
"      Salpeter SR, Luo EJ, Malter DS, Stuart B. Systematic review of noncancer presentations with a median survival of 6 months or less. Am J Med 2012; 125:512.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/24\">",
"      Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/25\">",
"      Fried TR, Bradley EH, O'Leary J. Prognosis communication in serious illness: perceptions of older patients, caregivers, and clinicians. J Am Geriatr Soc 2003; 51:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/26\">",
"      Marwit SJ, Datson SL. Disclosure preferences about terminal illness: an examination of decision-related factors. Death Stud 2002; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/27\">",
"      Kaplowitz SA, Campo S, Chiu WT. Cancer patients' desires for communication of prognosis information. Health Commun 2002; 14:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/28\">",
"      Goldstein D, Thewes B, Butow P. Communicating in a multicultural society. II: Greek community attitudes towards cancer in Australia. Intern Med J 2002; 32:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/29\">",
"      Elwyn TS, Fetters MD, Gorenflo W, Tsuda T. Cancer disclosure in Japan: historical comparisons, current practices. Soc Sci Med 1998; 46:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/30\">",
"      Li S, Chou JL. Communication with the cancer patient in China. Ann N Y Acad Sci 1997; 809:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/31\">",
"      Sparks L, Mittapalli K. To know or not to know: the case of communication by and with older adult Russians diagnosed with cancer. J Cross Cult Gerontol 2004; 19:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/32\">",
"      Smith AK, Sudore RL, P&eacute;rez-Stable EJ. Palliative care for Latino patients and their families: whenever we prayed, she wept. JAMA 2009; 301:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/33\">",
"      Back AL, Arnold RM. Discussing prognosis: \"how much do you want to know?\" talking to patients who do not want information or who are ambivalent. J Clin Oncol 2006; 24:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/34\">",
"      Yoong J, Park ER, Greer JA, et al. Early palliative care in advanced lung cancer: a qualitative study. JAMA Intern Med 2013; 173:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/35\">",
"      Dale W, Hemmerich J, Bylow K, et al. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol 2009; 27:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/36\">",
"      Loewenstein G. Hot-cold empathy gaps and medical decision making. Health Psychol 2005; 24:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/37\">",
"      Mack JW, Cronin A, Keating NL, et al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol 2012; 30:4387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/38\">",
"      Girgis A, Sanson-Fisher RW. Breaking bad news: consensus guidelines for medical practitioners. J Clin Oncol 1995; 13:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19735/abstract/39\">",
"      Boyd EA, Lo B, Evans LR, et al. \"It's not just what the doctor tells me:\" factors that influence surrogate decision-makers' perceptions of prognosis. Crit Care Med 2010; 38:1270.",
"     </a>",
"    </li>",
"    <li>",
"     Butow P, Tattersall MHN, Stockler M. Discussing Prognosis and Communicating Risk. In: Handbook of Communication in Oncology and Palliative Care, Kissane D, Bultz B, Butow P, Finlay I (Eds), Oxford University Press, 2010.",
"    </li>",
"    <li>",
"     Smith RC. Patient-centered interviewing: an evidence-based method, Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83706 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19735=[""].join("\n");
var outline_f19_17_19735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11773317\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11773416\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11773282\">",
"      THE IMPORTANCE OF PROGNOSIS IN CLINICAL PRACTICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30374933\">",
"      Patient-important factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11773289\">",
"      RATIONALE FOR DISCUSSING PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11773296\">",
"      THE SCIENCE OF ESTIMATING PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11773303\">",
"      ASSESSING PATIENT AND/OR FAMILY READINESS TO DISCUSS PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11773310\">",
"      DISCUSSING PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30374957\">",
"      When to discuss prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30374967\">",
"      How to discuss prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30374926\">",
"      - Stepwise strategy for discussion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11773317\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/83706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/83706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/17/286\" title=\"table 1\">",
"      Clinical decisions and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/3/13371\" title=\"table 2\">",
"      NURSE acronym",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=related_link\">",
"      Predicting the severity of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=related_link\">",
"      Survival estimates in advanced terminal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_17_19736="HCC surgical resection Gross";
var content_f19_17_19736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Hepatocellular carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 457px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Series of photographs taken during resection of a hepatocellular carcinoma in a patient with Child's A cirrhosis due to chronic hepatitis C. The upper two panels demonstrate the tumor projecting from the inferior aspect of the left lobe of the liver (arrows). The nodular surface of the liver is apparent, indicating underyling cirrhosis. The bottom panel illustrates the resection specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard B Freeman, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19736=[""].join("\n");
var outline_f19_17_19736=null;
var title_f19_17_19737="Pharmacologic treatment of essential tremor";
var content_f19_17_19737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic treatment of essential tremor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19737/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19737/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19737/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19737/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19737/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/17/19737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremor is defined as a rhythmic and oscillatory movement of a body part with a relatively constant frequency and variable amplitude. It is caused by either alternating or synchronous contractions of antagonistic muscles. Tremor is the most common of all movement disorders, and essential tremor (ET) is the most common neurologic cause of postural or action tremor.",
"   </p>",
"   <p>",
"    The criteria for ET and methods for distinguishing this from other tremors are shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef62078 \" href=\"UTD.htm?6/5/6235\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60694 \" href=\"UTD.htm?36/56/37771\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54735 \" href=\"UTD.htm?15/48/16139\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of tremor\", section on 'Essential tremor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the medical treatment of ET. The surgical treatment of medically refractory ET is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=see_link\">",
"     \"Surgical treatment of essential tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classification, clinical features, and evaluation of tremor are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link\">",
"     \"Overview of tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BETA BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are the most commonly used medications for the treatment of ET. The efficacy of beta blockers has been demonstrated primarily for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , and most of the studies evaluated short-term therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Propranolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines published by the American Academy of Neurology (AAN) in 2005 and updated in 2011 concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , 60 to 320",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    is effective for the treatment of limb tremor associated with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This conclusion is supported by the findings from 12 well-designed, prospective, randomized controlled clinical trials and a systematic review published in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/3\">",
"     3",
"    </a>",
"    ]. Tremor magnitude was reduced by about 50 percent as measured by accelerometry, and clinical rating scales also improved by about 50 percent. The mean dose of propranolol was 185.2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in nine of these studies.",
"   </p>",
"   <p>",
"    Long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (propranolol LA) is also effective for the treatment of ET and appears to provide the same therapeutic response as conventional propranolol [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ]. One study found that propranolol LA was preferred to conventional propranolol by 87 percent of patients because of ease of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AAN guidelines concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    probably reduces head tremor in ET, although the data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The best designed study, a randomized controlled trial involving 18 patients, found that propranolol reduced head tremor amplitude by about 50 percent, as measured by accelerometry [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/5\">",
"     5",
"    </a>",
"    ]. However, propranolol was not effective for head tremor in two smaller studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    taken in anticipation of social situations that are likely to exacerbate tremor are useful in some patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    side effects, including lightheadedness, fatigue, impotence, and bradycardia, occurred in 12 to 66 percent of patients in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    may be relatively contraindicated in the presence of heart block, asthma, or type 1 diabetes mellitus. However, propranolol may be used in patients with stable heart failure due to left ventricular systolic dysfunction, unless there are clear contraindications, such as unstable heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link&amp;anchor=H3#H3\">",
"     \"Major side effects of beta blockers\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AAN advises consultation with a cardiologist prior to starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in patients with cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A selective beta-1 adrenergic blocker such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    can be used instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in patients with asthma or bronchospasm. However, beta-1 selectivity is not absolute and may diminish at higher doses (eg, &gt;100 mg daily). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, the data regarding efficacy of other beta blockers are not as strong as the data supporting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       Atenolol",
"      </a>",
"      , a selective beta adrenergic blocker, probably reduces limb tremor associated with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ]. Two small randomized trials found that atenolol improved symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/8\">",
"       8",
"      </a>",
"      ] or accelerometer readings [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/9\">",
"       9",
"      </a>",
"      ] compared with placebo. In the first study, which only included nine patients, atenolol was less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/8\">",
"       8",
"      </a>",
"      ]; the second found that both atenolol and propranolol were similarly effective compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      , a nonselective beta adrenergic receptor blocker, probably reduces limb tremor associated with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ], as demonstrated in one well-designed randomized controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       Nadolol",
"      </a>",
"      , a nonselective beta adrenergic receptor blocker, possibly reduces limb tremor associated with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ], as shown in a small randomized controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/11\">",
"       11",
"      </a>",
"      ]. However, the benefit was found only for patients who previously responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       Metoprolol",
"      </a>",
"      , a selective beta adrenergic blocker, is of uncertain benefit for ET, as data regarding its effectiveness are conflicting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ]. A randomized controlled trial found that a single dose of metoprolol 150 mg was effective for improving tremor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/12\">",
"       12",
"      </a>",
"      ]. However, a subsequent small randomized, double-blind, crossover study found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      improved outcomes compared with placebo, but metoprolol did not [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"       Pindolol",
"      </a>",
"      probably does not reduce limb tremor associated with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,3\">",
"       1,3",
"      </a>",
"      ], as demonstrated in a well-designed randomized controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    may be effective for ET, in most instances there is no particular advantage to using these drugs compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , and the evidence is stronger for the latter. However, nadolol may still have a role, as it is a largely peripheral acting beta blocker and may avoid adverse central effects that are sometimes induced by propranolol (eg, depression).",
"   </p>",
"   <p>",
"    Although data are limited, it appears that patients who do not respond to adequate doses of one beta blocker for ET are unlikely to respond to another [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTICONVULSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     Primidone",
"    </a>",
"    is effective for the treatment of ET, and the anticonvulsants",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    probably reduce limb tremor associated with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AAN guidelines concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    , up to 750",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    is effective for the treatment of limb tremor associated with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This conclusion is supported by the findings of four well-designed, prospective, randomized controlled clinical trials that evaluated primidone for the treatment of ET and a systematic review published in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/3\">",
"     3",
"    </a>",
"    ]. In these studies, tremor magnitude was reduced by about 50 percent as measured by accelerometry, and clinical rating scales also improved by about 50 percent, an effect similar to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    . The mean dose of primidone, available from three of these studies, was 481.7",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Side",
"    effects from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    were typically more severe at treatment initiation, and they included sedation, drowsiness, fatigue, depression nausea, vomiting, ataxia, malaise, dizziness, unsteadiness, confusion, vertigo, and an acute toxic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ]. Primidone tolerability was not improved in a well-designed trial by use of a very low initial dose (7.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and slow titration (increasing by 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 20 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/15\">",
"     15",
"    </a>",
"    ]. Primidone may be better tolerated in patients with epilepsy in whom hepatic enzymes have been induced by the previous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    or other anticonvulsant drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    in ET is unknown; it is converted to phenylethylmalonamide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , but neither of these agents alone appears to have a significant effect on tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     Primidone",
"    </a>",
"    should be started at 25 mg (using one-half of the available 50 mg tablet) before sleep and should be titrated up carefully over several weeks as tolerated and according to therapeutic response. One suggested regimen is to increase in 25 mg increments every three to four days according to response and side effects (mainly sedation), stopping at 250 mg if there is no benefit. If there is a partial response at 250 mg nightly, the titration can continue up towards 500 mg nightly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Coadministration of a beta blocker and primidone may provide useful additive therapeutic benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    as monotherapy probably reduces limb tremor associated with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The evidence comes from one well-designed randomized controlled trial, which found that gabapentin 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduced tremor compared with placebo, and reduced tremor magnitude at day 15 by 77 percent as assessed by accelerometry [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/21\">",
"     21",
"    </a>",
"    ]. Gabapentin is associated with fewer side effects than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    as adjunct therapy has shown conflicting results for the treatment of ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,22,23\">",
"     1,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    probably reduces limb tremor associated with ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], but its use is associated with a relatively high rate of adverse effects.",
"   </p>",
"   <p>",
"    The largest controlled trial randomly assigned 223 patients with moderate to severe ET to 24 weeks of treatment with placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (target dose 400 mg daily) as either monotherapy or adjunct therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/24\">",
"     24",
"    </a>",
"    ]. Topiramate treatment at a mean final dose of 292 mg daily resulted in a significantly greater improvement in a tremor rating scale, the primary outcome measure, than placebo. The degree of clinical improvement with topiramate was considered moderate, whereas that seen with placebo was mild. However, the rate of treatment-limiting adverse events was higher with topiramate than placebo (31.9 versus 9.5 percent, respectively).",
"   </p>",
"   <p>",
"    In a later review that pooled the results of three small randomized controlled crossover trials with a total of 62 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    led to significant tremor reduction and improved functional disability compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/25\">",
"     25",
"    </a>",
"    ]. Adverse effects, including nausea, paresthesia, and concentration difficulty, were common in the topiramate-treated patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other anticonvulsants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       Phenobarbital",
"      </a>",
"      treatment for ET has shown conflicting outcomes in a limited number of trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       Levetiracetam",
"      </a>",
"      , although not well studied for ET, appears to have no significant benefit in most reports [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/26-30\">",
"       26-30",
"      </a>",
"      ]. A 2011 systematic review of treatment for ET concluded that levetiracetam is ineffective [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/3\">",
"       3",
"      </a>",
"      ], and the updated 2011 AAN guidelines state it probably does not reduce limb tremor in ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       Zonisamide",
"      </a>",
"      treatment reduced tremor severity in two small open label studies at doses of up to 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/31,32\">",
"       31,32",
"      </a>",
"      ], but was ineffective in other small trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       Pregabalin",
"      </a>",
"      treatment has shown inconsistent benefit in small trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/3,35,36\">",
"       3,35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADDITIONAL AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol has long been known to ameliorate ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], and alcohol appears to be beneficial for ET-related gait ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/39\">",
"     39",
"    </a>",
"    ]. The use of small amounts of alcohol before meals or social events is not unreasonable and is commonly practiced. However, the regular use of alcohol to manage tremor is not recommended. Over an extended period of time this leads to tolerance, with a need for increasingly larger amounts of alcohol to achieve the same effect, plus the added problem of superimposed withdrawal tremor overnight or when alcohol is omitted. Concerns for an increased incidence of alcohol addiction in patients with ET are unfounded [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral 1-octanol has shown promise in preliminary studies as treatment for ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. No intoxication was observed. Further efficacy trials of this agent are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are widely used because of the usually mistaken belief that tremor is due to anxiety. On the other hand, if tremor is aggravated by anxiety, an anxiety lowering medication may partially reduce tremor. Caution is urged with use of benzodiazepines for ET because of the potential for abuse, as well as the potential for drug discontinuation to cause withdrawal symptoms and exacerbation of tremor. These problems make benzodiazepines a second-line choice for the chronic treatment of ET.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       Alprazolam",
"      </a>",
"      is probably effective for the treatment of limb tremor associated with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Two clinical trials found that alprazolam, 0.125 to 3",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      was associated with an improvement in clinical rating scales of 25 to 34 percent compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Side effects included mild sedation and fatigue.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       Clonazepam",
"      </a>",
"      is possibly effective for the treatment of limb tremor associated with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. One clinical trial found that clonazepam 0.5 to 6",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      significantly reduced tremor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/45\">",
"       45",
"      </a>",
"      ], while another study found that clonazepam 0.4 to 4",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      was not effective and resulted in a 40 percent study completion rate due to drowsiness [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin type A (BoNT-A) injections have modest benefit for limb tremor associated with ET and are associated with dose-dependent hand weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ]. BoNT-A may reduce head tremor and voice tremor associated with ET, but data are limited, and BoNT-A for voice tremor is associated with side effects including breathiness, hoarseness, and swallowing difficulty. These conclusions come from the 2005 American Academy of Neurology (AAN) guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ] and were unchanged in the 2011 update [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/2\">",
"     2",
"    </a>",
"    ]. The data supporting these observations are summarized here for limb, head, and voice tremor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six studies involving 210 patients evaluated BoNT-A for limb tremor associated with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ]. The technique involves injecting BoNT-A into forearm muscles (flexor carpi radialis and ulnaris, and extensor carpi radialis and ulnaris muscles). The highest quality study was a randomized controlled trial involving 133 patients who were randomly assigned to low-dose BoNT-A (50 U), high-dose BoNT-A (100 U), or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/47\">",
"       47",
"      </a>",
"      ]. Short-term improvement in clinical rating scales was reported, but there was no consistent improvement in motor tasks or functional disability. Dose-dependent hand weakness was observed for the low and high-dose BoNT-A groups (30 and 70 percent, respectively).",
"      <br/>",
"      <br/>",
"      Additional side effects of BoNT-A included injection site pain, stiffness, cramping, hematoma, and paresthesias [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/47\">",
"       47",
"      </a>",
"      ]. These side effects are likely to have interfered with blinded treatment and evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three studies involving 62 patients evaluated BoNT-A for head tremor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ]. Injection sites included bilateral sternocleidomastoid and splenius capitis muscles. A clinical trial involving 10 patients found that more patients receiving BoNT-A than placebo injections had improvements on clinical rating scales and subjective rating scales, but the differences did not reach statistical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/48\">",
"       48",
"      </a>",
"      ]. Neck weakness and post-injection pain occurred in most patients. An open-label study found that BoNT-A injection was associated with significant improvement in tremor amplitude by accelerometry compared with baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three studies involving 25 patients evaluated BoNT-A for voice tremor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"       1",
"      </a>",
"      ]. One study involving 15 patients found that self-reported benefit after BoNT-A occurred in 10 patients (67 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/50\">",
"       50",
"      </a>",
"      ]. Side effects included voice weakness and breathiness lasting for one to two weeks after treatment in 12 patients (80 percent), and hoarseness and swallowing difficulty for four weeks in three patients (20 percent). Another study found that tremor severity was reduced after bilateral vocal cord injection in 3 of 10 patients (30 percent), and tremor was reduced after unilateral injection in two of nine patients (22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All the studies evaluated BoNT-A; no clinical studies using botulinum toxin type B for ET were identified by the AAN guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the United States, three different types of BoNT-A are marketed, which are designated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Botulinum toxin type A (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"       abobotulinumtoxinA",
"      </a>",
"      , Dysport&reg;)",
"     </li>",
"     <li>",
"      Botulinum toxin type A (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"       incobotulinumtoxinA",
"      </a>",
"      , Xeomin&reg;)",
"     </li>",
"     <li>",
"      Botulinum toxin type A (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      , Botox&reg;)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another systematic review of treatment of essential tremor published in 2011 concluded that botulinum toxin is possibly effective for the treatment of essential hand tremor, with a beneficial effect that is modest at best [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/3\">",
"     3",
"    </a>",
"    ]. Side effects include the risk of causing hand weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other oral drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other drugs have been used to treat ET. The following levels of effectiveness were derived from the 2005 AAN guidelines on drug therapies for ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ] as updated in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/2\">",
"     2",
"    </a>",
"    ], and from a separate systematic review published in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Possibly effective",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"     Nimodipine",
"    </a>",
"    , a calcium channel blocker, is possibly effective for limb tremor associated with ET at a dose of 30 mg four times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2,52\">",
"     1,2,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Uncertain effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , glutethimide, L-tryptophan combined with pyridoxine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    , octanol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    , and sodium oxybate have uncertain effectiveness for the treatment of ET; the available data for these drugs are limited or conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ineffective",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , carisbamate, 3,4-diaminopyridine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41652?source=see_link\">",
"     methazolamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    are probably not effective for treating ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, ET can be managed by primary care clinicians, beginning with exclusion of secondary causes and followed by initiation of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    . The decision to refer to a neurologist depends in part upon the ease or difficulty of achieving a satisfactory therapeutic response to medical treatment, as well the comfort level of the primary care clinician with use of agents such as anticonvulsants.",
"   </p>",
"   <p>",
"    Several important treatment issues have been addressed by a guideline on therapies for ET published by the AAN in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ], including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choice of initial therapy",
"     </li>",
"     <li>",
"      Utility of combined therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"     </li>",
"     <li>",
"      Evidence of sustained benefit of pharmacologic treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Choice of initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    have similar effectiveness when used as initial treatment for ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ]. Evidence supporting this observation comes from three small clinical trials that compared the two drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In the first of these, both propranolol and primidone significantly reduced limb tremor compared with placebo, and there was no significant difference between the two drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/53\">",
"     53",
"    </a>",
"    ]. Equivalent tremor reduction was found in the second trial after one week of propranolol treatment and two weeks of primidone treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute adverse reactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    and chronic side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    appear to be important limitations to the use of these drugs. This observation is supported by results of an open-label study that examined the acute and chronic effects of propranolol and primidone for ET in 50 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/55\">",
"     55",
"    </a>",
"    ]. No therapeutic effect was found for propranolol in 7 of 23 patients (30 percent) and no therapeutic effect for primidone in 7 of 22 (32 percent). Chronic side effects of propranolol, including fatigue, impotence, and bradycardia, led to discontinuation in an additional four patients (17 percent). Transient acute side effects of primidone, including nausea, ataxia, dizziness, sedation, and confusion, occurred in eight patients (36 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Combined propranolol and primidone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    may be used in combination to treat limb tremor in ET, and the combined use of these drugs is possibly more effective than either drug alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ]. The evidence cited by the AAN guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ] supporting this observation includes two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/17,56\">",
"     17,56",
"    </a>",
"    ], although no double-blind randomized controlled trials have addressed the use of combined therapy for ET.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      monotherapy at the maximum effective dose (average 260",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      reduced tremor amplitude by a mean of 35 percent; the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      , 50 to 1000",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      decreased tremor amplitude by a mean of 60 to 70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/17\">",
"       17",
"      </a>",
"      ]. Acute reactions to primidone, including ataxia and confusion, occurred in 12 percent, and primidone titration was limited in others because of sedation and vertigo.",
"     </li>",
"     <li>",
"      In a second study, the combined use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      was more effective than either drug alone for the treatment of postural and kinetic tremor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Duration of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    maintain effective limb tremor reduction in the majority of patients for at least one year, although increased doses of both drugs may be needed by 12 months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"     1",
"    </a>",
"    ]. This observation from the AAN guideline is supported by the results of several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/55,57-59\">",
"     55,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small open-label extension study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      (375 to 750",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      treatment was effective for up to one year [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another small open-label extension trial found that the initial therapeutic benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      was maintained for months, but that 5 of 12 patients (42 percent) required an increased dose at 12 months compared with the dose at three to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a double-blind trial involving 113 patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      at both low (250",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and high (750",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      doses was effective for ET, and benefit was maintained for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An open-label study of long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      for ET in 50 patients found that benefit continued after one year of propranolol treatment in 10 of 25 patients (40 percent); the dose of propranolol was increased in six of the 10 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/55\">",
"       55",
"      </a>",
"      ]. Continued benefit at one year was seen with primidone in over 50 percent of patients. Reduction in therapeutic benefit (ie, tolerance) with chronic propranolol and primidone treatment occurred in 12.5 and 13 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/14/13538?source=see_link\">",
"       \"Patient information: Tremor (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/6/34913?source=see_link\">",
"       \"Patient information: Tremor (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations for the treatment of essential tremor (ET) are based upon guidelines published by the American Academy of Neurology (AAN) in 2005 and updated in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], subsequent developments in therapeutics, and the author's clinical experience.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      (or propranolol LA), 60 to 320",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      is effective for the treatment of limb tremor associated with ET. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Propranolol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       Primidone",
"      </a>",
"      , up to 750",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      is effective for the treatment of limb tremor associated with ET. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Primidone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      have similar effectiveness when used as initial therapy to treat limb tremor in ET, and either drug may be used depending on concurrent medical problems and potential side effects. While both drugs are recommended by the AAN guidelines as first-line agents, we suggest that the use of primidone be reserved for patients who either do not tolerate or do not respond to propranolol. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Choice of initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      can be used at doses of 60 to 320",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to reduce limb tremor associated with ET; maximum tremor suppression is more likely to occur with a dose between 160 and 320",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Relative contraindications to propranolol include heart block and bronchospastic disease. Propranolol use can also be limited by other chronic side effects such as lightheadedness, fatigue, impotence, and bradycardia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Propranolol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       Primidone",
"      </a>",
"      treatment should begin at a dose of 12.5 to 25 mg before sleep and be titrated carefully over several weeks as tolerated and according to therapeutic response, up to 750",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Use of primidone can be limited by side effects, often acute, such as sedation, drowsiness, fatigue, nausea, vomiting, ataxia, malaise, dizziness, unsteadiness, vertigo, and confusion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Primidone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      maintain effective limb tremor reduction in the majority of patients for at least one year. The doses of propranolol and primidone may need to be increased by 12 months of therapy when treating limb tremor. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Duration of benefit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combined use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      is possibly more effective than either drug alone. Coadministration of propranolol and primidone is suggested if the therapeutic response to either drug alone is suboptimal for the treatment of limb tremor in ET. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Combined propranolol and primidone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      probably reduces head tremor in ET, although the data are limited. Propranolol should be considered for treatment of head tremor in patients with ET. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Propranolol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Single doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      can be used in anticipation of social situations that are likely to exacerbate tremor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Propranolol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The beta blockers",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , and the anticonvulsants",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      (monotherapy) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      are suggested as treatment of limb tremor associated with ET for patients who do not respond to or do not tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Other beta blockers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Gabapentin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Topiramate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       Alprazolam",
"      </a>",
"      is probably effective for limb tremor with ET but should be used with caution due to its abuse potential. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       Atenolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      , selective beta adrenergic blockers, are suggested instead of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      as treatment of limb tremor in ET for patients with asthma or bronchospasm, particularly those who are unable to tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Other beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcohol may ameliorate ET, but regular use is discouraged because of potential long-term adverse effects and risk for rebound tremor exacerbation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Alcohol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Botulinum toxin type A (BoNT-A) injections have modest benefit for ET-related limb tremor, but they are associated with dose-dependent hand weakness. BoNT-A treatment for ET-associated limb, head, and voice tremor is suggested only for medically refractory cases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Botulinum toxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery (unilateral thalamotomy or thalamic deep brain stimulation of the thalamic ventral intermediate nucleus) is effective treatment for contralateral limb tremor in patients with ET who fail medical therapy and are severely impaired. Surgery for ET is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=see_link\">",
"       \"Surgical treatment of essential tremor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/1\">",
"      Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005; 64:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/2\">",
"      Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011; 77:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/3\">",
"      Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol 2011; 10:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/4\">",
"      Koller WC. Long-acting propranolol in essential tremor. Neurology 1985; 35:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/5\">",
"      Koller WC. Propranolol therapy for essential tremor of the head. Neurology 1984; 34:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/6\">",
"      Sweet RD, Blumberg J, Lee JE, Mc Dowell FH. Propranolol treatment of essential tremor. Neurology 1974; 24:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/7\">",
"      Calzetti S, Sasso E, Negrotti A, et al. Effect of propranolol in head tremor: quantitative study following single-dose and sustained drug administration. Clin Neuropharmacol 1992; 15:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/8\">",
"      Jefferson D, Jenner P, Marsden CD. beta-Adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry 1979; 42:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/9\">",
"      Larsen TA, Ter&auml;v&auml;inen H, Calne DB. Atenolol vs. propranolol in essential tremor. A controlled, quantitative study. Acta Neurol Scand 1982; 66:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/10\">",
"      Leigh PN, Jefferson D, Twomey A, Marsden CD. Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J Neurol Neurosurg Psychiatry 1983; 46:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/11\">",
"      Koller WC. Nadolol in essential tremor. Neurology 1983; 33:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/12\">",
"      Calzetti S, Findley LJ, Gresty MA, et al. Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry 1981; 44:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/13\">",
"      Calzetti S, Findley LJ, Perucca E, Richens A. Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor. J Neurol Neurosurg Psychiatry 1982; 45:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/14\">",
"      Teravainen H, Larsen A, Fogelholm R. Comparison between the effects of pindolol and propranolol on essential tremor. Neurology 1977; 27:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/15\">",
"      O'Suilleabhain P, Dewey RB Jr. Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord 2002; 17:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/16\">",
"      O'Brien MD, Upton AR, Toseland PA. Benign familial tremor treated with primidone. Br Med J (Clin Res Ed) 1981; 282:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/17\">",
"      Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology 1986; 36:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/18\">",
"      Calzetti S, Findley LJ, Pisani F, Richens A. Phenylethylmalonamide in essential tremor. A double-blind controlled study. J Neurol Neurosurg Psychiatry 1981; 44:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/19\">",
"      Sasso E, Perucca E, Calzetti S. Double-blind comparison of primidone and phenobarbital in essential tremor. Neurology 1988; 38:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/20\">",
"      Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry 1985; 48:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/21\">",
"      Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999; 56:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/22\">",
"      Ondo W, Hunter C, Vuong KD, et al. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord 2000; 15:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/23\">",
"      Pahwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 1998; 13:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/24\">",
"      Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006; 66:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/25\">",
"      Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol 2008; 31:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/26\">",
"      Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004; 19:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/27\">",
"      Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology 2005; 64:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/28\">",
"      Elble RJ, Lyons KE, Pahwa R. Levetiracetam is not effective for essential tremor. Clin Neuropharmacol 2007; 30:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/29\">",
"      Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004; 27:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/30\">",
"      Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for the treatment of essential tremor. Mov Disord 2005; 20:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/31\">",
"      Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord 2009; 24:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/32\">",
"      Ondo WG. Zonisamide for essential tremor. Clin Neuropharmacol 2007; 30:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/33\">",
"      Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 2007; 22:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/34\">",
"      Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 2005; 11:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/35\">",
"      Zesiewicz TA, Ward CL, Hauser RA, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007; 22:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/36\">",
"      Ferrara JM, Kenney C, Davidson AL, et al. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci 2009; 285:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/37\">",
"      Growdon JH, Shahani BT, Young RR. The effect of alcohol on essential tremor. Neurology 1975; 25:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/38\">",
"      Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology 1984; 34:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/39\">",
"      Klebe S, Stolze H, Grensing K, et al. Influence of alcohol on gait in patients with essential tremor. Neurology 2005; 65:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/40\">",
"      Koller WC. Alcoholism in essential tremor. Neurology 1983; 33:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/41\">",
"      Bushara KO, Goldstein SR, Grimes GJ Jr, et al. Pilot trial of 1-octanol in essential tremor. Neurology 2004; 62:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/42\">",
"      Shill HA, Bushara KO, Mari Z, et al. Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. Neurology 2004; 62:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/43\">",
"      Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology 1988; 38:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/44\">",
"      Gunal DI, Af��ar N, Bekiroglu N, Aktan S. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci 2000; 21:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/45\">",
"      Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology 1987; 37:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/46\">",
"      Thompson C, Lang A, Parkes JD, Marsden CD. A double-blind trial of clonazepam in benign essential tremor. Clin Neuropharmacol 1984; 7:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/47\">",
"      Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/48\">",
"      Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology 1995; 45:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/49\">",
"      Wissel J, Masuhr F, Schelosky L, et al. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 1997; 12:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/50\">",
"      Herteg&aring;rd S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol 2000; 109:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/51\">",
"      Warrick P, Dromey C, Irish JC, et al. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope 2000; 110:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/52\">",
"      Heilman KM. Orthostatic tremor. Arch Neurol 1984; 41:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/53\">",
"      Gorman WP, Cooper R, Pocock P, Campbell MJ. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry 1986; 49:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/54\">",
"      Dietrichson P, Espen E. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels. Acta Neurol Scand 1987; 75:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/55\">",
"      Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989; 39:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/56\">",
"      Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986; 36:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/57\">",
"      Sasso E, Perucca E, Fava R, Calzetti S. Primidone in the long-term treatment of essential tremor: a prospective study with computerized quantitative analysis. Clin Neuropharmacol 1990; 13:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/58\">",
"      Calzetti S, Sasso E, Baratti M, Fava R. Clinical and computer-based assessment of long-term therapeutic efficacy of propranolol in essential tremor. Acta Neurol Scand 1990; 81:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19737/abstract/59\">",
"      Serrano-Due&ntilde;as M. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord 2003; 10:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4898 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19737=[""].join("\n");
var outline_f19_17_19737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BETA BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Propranolol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTICONVULSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADDITIONAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other oral drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Possibly effective",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Uncertain effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ineffective",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PHARMACOLOGIC TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Choice of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Combined propranolol and primidone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Duration of benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4898|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/5/6235\" title=\"table 1\">",
"      Criteria for essential tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/56/37771\" title=\"table 2\">",
"      Parkinson vs essential tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/48/16139\" title=\"table 3\">",
"      Signs of nonessential tremor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=related_link\">",
"      Overview of tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/6/34913?source=related_link\">",
"      Patient information: Tremor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/14/13538?source=related_link\">",
"      Patient information: Tremor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=related_link\">",
"      Surgical treatment of essential tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_17_19738="Recommendations for the use of human papillomavirus vaccines";
var content_f19_17_19738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recommendations for the use of human papillomavirus vaccines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19738/contributors\">",
"     Philip E Castle, PhD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19738/contributors\">",
"     J Thomas Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19738/contributors\">",
"     Joel M Palefsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19738/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/17/19738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/17/19738/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/17/19738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus is a sexually transmitted pathogen that causes anogenital disease in males and females. Persistent viral infection with high-risk human papillomavirus (HPV) genotypes causes virtually all cancers of the cervix. The same HPV genotypes (or &ldquo;types&rdquo;) that cause cancer of the cervix also cause most cases of anal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/1\">",
"     1",
"    </a>",
"    ]. Two vaccines have been developed against HPV infection; one is a quadrivalent vaccine (Gardasil) and the other is a bivalent vaccine (Cervarix). The United States Food and Drug Administration approved Gardasil in 2006 and Cervarix in 2009 for the prevention of HPV-related diseases as described below.",
"   </p>",
"   <p>",
"    This topic will cover issues related to routine immunization recommendations, vaccination in special patient populations, and vaccine safety. The natural history, details on epidemiology, and immunology of HPV infection, as well as clinical trial data on HPV vaccines are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link\">",
"     \"Clinical trials of human papillomavirus vaccines\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26229?source=see_link\">",
"     \"The life cycle, natural history, and immunology of human papillomaviruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16844157\">",
"    <span class=\"h2\">",
"     HPV-related disease in females",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967919\">",
"    <span class=\"h3\">",
"     Cervical cancer and precursor lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer is the third most common female cancer worldwide, with an estimated incidence of 530,000 in 2008; the attributable fraction due to HPV infection was estimated to be 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/2\">",
"     2",
"    </a>",
"    ]. HPV types 16 and 18 cause approximately 70 percent of cervical cancers and 50 percent of precancerous cervical lesions (ie, cervical intraepithelial neoplasia grade 2 and grade 3 or",
"    <span class=\"nowrap\">",
"     CIN2/3).",
"    </span>",
"    The estimated annual incidence in the United States of CIN among females who undergo cervical cancer screening is 0.4 percent for CIN 1 and 0.5 percent for CIN 2,3 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link&amp;anchor=H2#H2\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16844243\">",
"    <span class=\"h3\">",
"     Vulvar and vaginal cancer and precursor lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar and vaginal cancer are rare cancers globally, with an estimated incidence of 27,000 vulvar cancers and 13,000 vaginal cancers in 2008; the attributable fraction due to HPV infection was estimated to be 43 percent for vulvar cancer and 70 percent for vaginal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/2\">",
"     2",
"    </a>",
"    ]. HPV 16 and HPV 18 cause approximately 60 percent of HPV-positive vaginal cancers and precancerous vaginal lesions; HPV 16 and HPV 18 cause approximately 35 percent of HPV-positive vulvar cancers and 75 percent of precancerous vulvar lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link\">",
"     \"Vaginal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16844286\">",
"    <span class=\"h2\">",
"     HPV-related disease in females and males",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2351179\">",
"    <span class=\"h3\">",
"     Anal cancer and precursor lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal cancer is a rare cancer globally, with an estimated incidence of 27,000 in 2008; the attributable fraction due to HPV is 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/2\">",
"     2",
"    </a>",
"    ]. HPV types 16 and 18 cause approximately 70 percent of anal cancers and precancerous anal lesions (ie, anal intraepithelial neoplasia grade 2 and grade 3 or",
"    <span class=\"nowrap\">",
"     AIN2/3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Although it remains an uncommon cancer, the incidence of anal cancer is increasing in the United States and other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In data from the Surveillance, Epidemiology and End Results program of the National Cancer Institute, the annual incidence among males and females between 1994 and 2000 was approximately 2 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/6\">",
"     6",
"    </a>",
"    ]. The rate of anal cancer among men who have sex with men (MSM) was estimated to be as high as 37 per 100,000 prior to the HIV epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/8\">",
"     8",
"    </a>",
"    ], and the incidence of anal cancer among HIV-positive MSM is estimated to be approximately twice that of HIV-negative MSM [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12761?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification and epidemiology of anal cancer\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2351186\">",
"    <span class=\"h3\">",
"     Genital warts",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV types 6 and 11 also cause 90 percent of genital warts. The incidence of HPV infection was evaluated in 8800 females who were enrolled in the placebo arms of two randomized trials of the HPV quadrivalent vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/11\">",
"     11",
"    </a>",
"    ]. Three percent of the placebo recipients developed genital warts over approximately four years, the vast majority of which were associated with HPV 6 or HPV 11 infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link&amp;anchor=H746880#H746880\">",
"     \"Epidemiology of human papillomavirus infections\", section on 'Genital warts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital warts are associated with physical and psychological morbidity and have a high rate of treatment failure; furthermore, treatment of recurrent episodes is costly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16844306\">",
"    <span class=\"h2\">",
"     HPV-related diseases in males",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16844314\">",
"    <span class=\"h3\">",
"     Penile cancer and precursor lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile cancer is rare globally, with an estimated incidence of 22,000 cancers in 2008; the attributable fraction due to HPV was 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/2\">",
"     2",
"    </a>",
"    ]. HPV 16 and HPV 18 cause approximately 35 to 40 percent of penile cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967752\">",
"    <span class=\"h1\">",
"     AVAILABLE VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gardasil, a quadrivalent HPV vaccine, targets HPV types 6, 11, 16, and 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/14\">",
"     14",
"    </a>",
"    ]. It is composed of 20 micrograms each of HPV types 6 and 18 L1 capsid protein-based virus-like particles (VLPs) and 40 micrograms each of HPV types 11 and 16 L1 capsid protein-based VLPs, with 225 micrograms amorphous aluminum hydroxyphosphate sulfate as an adjuvant. Gardasil is made using a recombinant protein expression in Saccharomyces cerevisiae (bread yeast) system. Cervarix, a bivalent vaccine, targets HPV types 16 and 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/15\">",
"     15",
"    </a>",
"    ]. It is composed of 20 micrograms each of HPV types 16 and 18 VLPs with a novel adjuvant called ASO4, which contains 500 micrograms",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    and 50 microgram 3-O-desacyl-4&rsquo; monophosphoryl lipid A (MPL), a detoxified derivative of the lipopolysaccharide (LPS) of the gram-negative bacterium Salmonella minnesota R595 strain. Cervarix is made using a recombinant protein expression in baculovirus (insect) cell system. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Vaccine dose and administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967957\">",
"    <span class=\"h1\">",
"     EFFICACY AND IMMUNOGENICITY IN FEMALES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16661848\">",
"    <span class=\"h2\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excellent antibody responses have been reported following immunization with both quadrivalent and bivalent vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Because efficacy studies were restricted to sexually active females, 15 years of age and older, immunological &ldquo;bridging&rdquo; studies were conducted in females aged 9 to 15 years to demonstrate safety and immunogenicity. Following vaccination with the quadrivalent vaccine, the vaccine geometric mean titers (GMT) after 18 months in females aged 9 to 15 years were two- to threefold higher than in females aged 16 to 26 years for all targeted types [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/19\">",
"     19",
"    </a>",
"    ]. Following vaccination with the bivalent vaccine, the GMT after seven months in females aged 10 to 14 years was noninferior to females aged 15 to 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a head-to-head comparison of the immunogenicity of quadrivalent and bivalent HPV vaccines, immunization with the bivalent vaccine induced geometric mean titers of serum neutralizing antibodies 2.3- to 4.8-fold higher for HPV 16 and 6.8- to 9.1-fold higher for HPV 18 across all age strata compared with the quadrivalent vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/21\">",
"     21",
"    </a>",
"    ]. Whether the induction of higher serum titers against HPV 16 and 18 has any impact on the degree and duration of protection is unknown. Furthermore, there is no defined minimum threshold titer for protection. Seroconversion from prior exposure has been shown to reduce the risk of incident HPV infection, suggesting that the titers resulting from natural infection, which are an order of magnitude lower than those elicited in vaccine studies, provide some level of protection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12598503\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A short summary of the major findings from randomized clinical trials of both HPV vaccines is found below. These trials were designed to determine if HPV immunization could prevent the development of cervical intraepithelial neoplasia",
"    <span class=\"nowrap\">",
"     (CIN2/3),",
"    </span>",
"    adenocarcinoma in situ, or cervical cancer related to HPV 16 or HPV 18 among females who had never been infected with HPV. In these studies, HPV status was determined through serologic testing and DNA detection in cervical specimens. Additionally, the incidence of genital warts and vaginal and vulvar intraepithelial neoplasia (VAIN and VIN 1-3) was also examined in patients receiving quadrivalent vaccine. A detailed discussion of these large clinical trials is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link\">",
"     \"Clinical trials of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no efficacy data regarding the prevention of anal intraepithelial neoplasia (AIN) and anal cancer in females specifically; however, since the majority of anal cancers in females are related to HPV 16 and HPV 18, a beneficial impact of vaccination to prevent anal intraepithelial neoplasia and anal cancer in females is anticipated. Based on these data and assumptions, prevention of AIN and anal cancer was added to the list of existing indications for vaccination in females with the quadrivalent vaccine. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Recommendations for HPV immunization in females'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Quadrivalent HPV vaccine (Gardasil)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of two large randomized clinical trials in more than 17,000 adolescents and young females are summarized below [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/19,24\">",
"     19,24",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical trials of human papillomavirus vaccines\", section on 'Quadrivalent HPV 6/11/16/18 L1 virus-like particle vaccine'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among HPV-na&iuml;ve populations, the efficacy of quadrivalent HPV vaccine for preventing CIN2 or more severe disease due to HPV types included in the vaccine, was 97 to 100 percent.",
"     </li>",
"     <li>",
"      In the overall population of study participants (with or without prior HPV infection), the efficacy of quadrivalent HPV vaccine for preventing CIN2, or more severe disease due to HPV types included in the vaccine was significantly lower at approximately 44 percent after a mean follow-up period of three years. This reduction in efficacy reflects the fact that the vast majority of enrollees in this trial were already sexually active and many had been previously infected with vaccine HPV types. (See",
"      <a class=\"local\" href=\"#H4761822\">",
"       'Timing of immunization'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gardasil is widely available and has been approved in many countries throughout the world for the prevention of cervical, vulvar, and vaginal cancers and their precursor lesions (ie, cervical, vulvar, and vaginal intraepithelial neoplasia) caused by HPV types 6, 11, 16, and 18 as well as genital warts caused by HPV 6 and 11.",
"   </p>",
"   <p>",
"    In 2010, the United States Food and Drug Administration (FDA), and many other health agencies worldwide, also approved the quadrivalent HPV vaccine for the prevention of anal intraepithelial neoplasia and anal cancer in females based on clinical trial results in males. Data on the efficacy of quadrivalent HPV vaccine in males for the prevention of genital warts and anal cancer are discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Efficacy and immunogenicity in males'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bivalent HPV vaccine (Cervarix)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of one large randomized clinical trial in more than 18,000 young females aged 15 to 25 years are summarized below [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/25\">",
"     25",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical trials of human papillomavirus vaccines\", section on 'Bivalent HPV 16/18 L1 virus-like particle vaccine'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among HPV-na&iuml;ve patients, the efficacy of the bivalent vaccine for preventing CIN2 or more severe disease due to HPV types included in the vaccine was 93 percent, comparable with the efficacy of the HPV quadrivalent vaccine.",
"     </li>",
"     <li>",
"      In the overall population of study participants (with and without prior HPV infection), vaccine efficacy for preventing CIN2 or more severe disease due to HPV types included in the vaccine was significantly lower at 53 percent after a mean follow-up period of approximately three years. These data are consistent with those seen with HPV quadrivalent vaccine and emphasize the need to vaccinate individuals before the onset of sexual activity to gain the greatest benefit and maximize cost effectiveness. (See",
"      <a class=\"local\" href=\"#H4761822\">",
"       'Timing of immunization'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cervarix is widely available and has been approved in many countries throughout the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR HPV IMMUNIZATION IN FEMALES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4761822\">",
"    <span class=\"h2\">",
"     Timing of immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial data of vaccine efficacy in males and females suggest that immunization with HPV vaccine is most effective among individuals who have not been infected with HPV (eg, patients who are &ldquo;HPV-na&iuml;ve&rdquo;). Thus, the optimal time for HPV immunization is prior to an individual&rsquo;s sexual debut. Neither vaccine treats or accelerates the clearance of preexisting vaccine-type HPV infections or related disease.",
"   </p>",
"   <p>",
"    Females who are sexually active should still be vaccinated consistent with age-specific recommendations. A history of an abnormal Papanicolaou test, genital warts, or HPV infection is NOT a contraindication to HPV immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/26\">",
"     26",
"    </a>",
"    ]. However, immunization is less beneficial for females who have already been infected with one of more of the HPV vaccine types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5968335\">",
"    <span class=\"h2\">",
"     Expert guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various guideline committees have made recommendations regarding the use of HPV vaccine, which are discussed below. While all guidelines target the same age group for routine vaccination, they differ in the catch-up age range. This is primarily due to cost-effectiveness analyses which show the benefit and cost effectiveness is lower when vaccination is given at older ages. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Cost effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Advisory Committee on Immunization Practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Advisory Committee on Immunization Practices (ACIP) recommends the bivalent or quadrivalent HPV vaccines for females aged 11 to 12 for the prevention of cervical, vaginal, and vulvar cancer and the related precursor lesions caused by the HPV types targeted by these vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/27\">",
"     27",
"    </a>",
"    ]. The ACIP also recommends the quadrivalent HPV vaccine for the prevention of anal cancer and its precursor lesions, and genital warts in females [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bivalent or quadrivalent vaccines can be administered to females as young as age nine. Catch-up vaccination is also recommended for females aged 13 to 26 years who have not been previously vaccinated or who have not completed their vaccine series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9255720\">",
"    <span class=\"h3\">",
"     Pediatric, gynecologic, and family practice societies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations from the American Academy of Pediatrics (AAP), the American Academy of Family Practice (AAFP), and the American College of Obstetricians and Gynecologists (ACOG) are all largely consistent with the ACIP guidelines above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     American Cancer Society",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the ACIP, the American Cancer Society (ACS) guidelines recommend that HPV vaccination should be routinely offered to females aged 11 to 12 years; immunization may begin at nine years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the ACS recommends catch-up vaccination for females aged 13 to 18 who have not been previously vaccinated or completed their vaccine series. The ACS notes that there is insufficient evidence to recommend for or against vaccination of females aged 19 to 26 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     World Health Organization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO)",
"    <a class=\"external\" href=\"file://www.who.int/wer/2009/wer8415.pdf\">",
"     position paper",
"    </a>",
"    suggests that girls within the age range of 9 through 13 years should be the primary target population for HPV immunization (",
"    <a class=\"external\" href=\"file://www.who.int/wer\">",
"     www.who.int/wer",
"    </a>",
"    ). It notes that local public health programs should recommend vaccination of older females only if it is affordable and cost effective and does not divert resources from vaccinating the primary target population or screening for cervical cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EFFICACY AND IMMUNOGENICITY IN MALES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in HPV vaccine efficacy and safety in young males has not only included prevention of HPV-related diseases (genital warts, anal cancer, and penile cancer), but also possible decreased transmission of HPV infection to female sex partners and potential for prevention of oral cancers associated with HPV 16 and 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16844411\">",
"    <span class=\"h2\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies with both quadrivalent HPV vaccine (Gardasil) and bivalent HPV vaccine (Cervarix) have demonstrated that the proportions of vaccine recipients who achieve seroconversion is comparable in males (eg, 99 to 100 percent) and females (eg, 93 to 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Similar adverse events profiles have also been documented; the most common side effect is pain at the injection site. Eighteen months following vaccination with the quadrivalent vaccine, the geometric mean titers against all four targeted types in males aged 9 to 15 years were noninferior to those in females of the same age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/34\">",
"     34",
"    </a>",
"    ]. Following vaccination with bivalent vaccine, the geometric mean titers against both targeted types in males aged 10 to 18 years and 10 to 14 years were higher than those historically reported for females aged 15 to 25 years and 10 to 14 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/33\">",
"     33",
"    </a>",
"    ]. As in females, there is no defined minimum threshold titer for protection in males. (See",
"    <a class=\"local\" href=\"#H16661848\">",
"     'Immunogenicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16844442\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a placebo-controlled international trial, the efficacy of quadrivalent HPV vaccine was evaluated among 4065 males aged 16 to 26 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical trials of human papillomavirus vaccines\", section on 'Quadrivalent vaccine (Gardasil) in males'",
"    </a>",
"    .) The following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of immunization against the development of external genital lesions and persistence of HPV infection (by HPV 6, 11, 16, or 18 types) was 90 percent and 86 percent, respectively, among HPV-na&iuml;ve males (no evidence of infection with the relevant HPV vaccine types at enrollment) who received all three doses of vaccine.",
"     </li>",
"     <li>",
"      In contrast, vaccine efficacy was significantly lower among the overall patient population with or without HPV infection at enrollment (66 percent for the prevention of external genital warts and 48 percent for the prevention of persistent HPV infection).",
"     </li>",
"     <li>",
"      The efficacy of HPV immunization in preventing anal intraepithelial neoplasia secondary to the relevant HPV vaccine types was assessed in a planned sub-study of 602 men who have sex with men (MSM). Similar to the above results, vaccine efficacy was higher in the HPV-na&iuml;ve compared with the overall MSM population (78 versus 50 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93840009\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR HPV IMMUNIZATION IN MALES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4762066\">",
"    <span class=\"h2\">",
"     Timing of immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial data of vaccine efficacy in males and females suggest that immunization with HPV vaccine is most effective among individuals who have not been infected with HPV (eg, patients who are &ldquo;HPV-na&iuml;ve&rdquo;). Thus, the optimal time for HPV immunization is prior to an individual&rsquo;s sexual debut. Neither vaccine treats or accelerates the clearance of preexisting vaccine-type HPV infections or related disease.",
"   </p>",
"   <p>",
"    Males who are sexually active may still be vaccinated consistent with age-specific recommendations. A history of anal intraepithelial neoplasia, genital warts, or HPV infection is NOT a contraindication to HPV immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/26\">",
"     26",
"    </a>",
"    ]. However, immunization is less beneficial for males who have already been infected with one or more of the HPV vaccine types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967227\">",
"    <span class=\"h2\">",
"     Expert guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In October 2011, the Advisory Committee on Immunization Practices (ACIP) recommended the routine use of quadrivalent vaccine in males aged 11 or 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/36\">",
"     36",
"    </a>",
"    ]. The vaccination series can be administered to individuals as young as nine years. Vaccination is also recommended for males aged 13 to 21 years who have not been vaccinated previously or who have not completed the three-dose series. For males who have sex with males (MSM) and for males who are immunocompromised (including HIV infection), ACIP recommends vaccination through age 26 for those not previously vaccinated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For other males, the ACIP supports &ldquo;permissive use&rdquo; of the quadrivalent vaccine in males aged 22 through 26 years. Permissive use means that the vaccine is recommended, but not considered to be of sufficient priority to include on routine vaccination schedules. Vaccines recommended on a permissive basis are less likely to be covered by a patient&rsquo;s health insurance company.",
"   </p>",
"   <p>",
"    The decision of the ACIP panel to recommend quadrivalent vaccine among males was based on: a) vaccine efficacy data on genital warts and persistent HPV infection and prevention of anal intraepithelial neoplasia in MSM [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/35,37\">",
"     35,37",
"    </a>",
"    ] and b) vaccine safety data [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/38\">",
"     38",
"    </a>",
"    ]. Cost-effectiveness analyses have suggested that male vaccination is less cost effective than female vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, the overall cost effectiveness of male vaccination depends on a range of assumptions, such as vaccine efficacy, vaccine coverage of females, the range of health outcomes included, and the effect of HPV-associated diseases on quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/36\">",
"     36",
"    </a>",
"    ]. Male vaccination may be more cost effective in the seeing of low vaccination coverage among females, which is the current situation in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967234\">",
"    <span class=\"h2\">",
"     Controversies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opponents of HPV immunization in males argue that [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The burden of HPV-associated diseases such as anal, penile, and oropharyngeal cancers in males is less than that of cervical cancer in females [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Public health initiatives should be most focused on attaining high rates of immunization in young girls as it is the most cost effective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proponents of HPV immunization in males argue that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunization rates in young girls have been generally low, particularly when immunizations are not mandatory [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/44\">",
"       44",
"      </a>",
"      ]. It is under these conditions that both incremental benefit and cost effectiveness of vaccinating males have been shown.",
"     </li>",
"     <li>",
"      High coverage programs in females confer protection against HPV-related infection and disease in heterosexual males, but not MSM.",
"     </li>",
"     <li>",
"      HPV infection is common in males and is readily transmitted, influencing disease rates in both males and females [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967614\">",
"    <span class=\"h1\">",
"     IMMUNIZATION IN SPECIAL PATIENT POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967665\">",
"    <span class=\"h2\">",
"     Pregnant females",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neither HPV vaccine contains live virus, use in pregnancy is not recommended because of limited data on safety [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/27\">",
"     27",
"    </a>",
"    ]. Lactating females can receive the immunization series since subunit vaccines do not affect the safety of infant breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a woman receives the HPV vaccine before she knows that she is pregnant she should be reassured that there is no evidence that this vaccine will harm the pregnancy. In the FUTURE II trial, pregnancy occurred in 1053 females in the vaccine group and 1106 in the placebo group; no obvious anomalies attributable to vaccine were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Females who have started the series, but become pregnant before completion of all three shots, may resume the series when postpartum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both vaccine manufacturers maintain pregnancy registries to monitor fetal outcomes of pregnant females exposed to HPV vaccine. Exposures to the quadrivalent vaccine can be reported by calling 800-986-8999 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/47\">",
"     47",
"    </a>",
"    ]. Exposures to the bivalent vaccine can be reported by calling 888-452-9622 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5968479\">",
"    <span class=\"h2\">",
"     Immunization in females with preexisting cervical abnormalities or genital warts",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of genital warts, abnormal cytology, or positive HPV DNA test result is not evidence of prior infection with any or all of the vaccine HPV types [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, the Advisory Committee on Immunization Practices (ACIP) recommends immunization for females (up to 26 years of age) with any such history [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. However, these patients should be advised that vaccination will have no therapeutic effect on preexisting HPV infection or abnormal cervical histology, and the potential benefit of HPV vaccination is not as great as if they were vaccinated before they started having sex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5968486\">",
"    <span class=\"h2\">",
"     Immunosuppressed or immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant recipients and HIV-infected patients, particularly those with low CD4 counts (&lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    are at risk for HPV-related disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link&amp;anchor=H15#H15\">",
"     \"HIV and women\", section on 'Abnormal cervical cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of the HPV quadrivalent vaccine in HIV-infected adult males [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/48\">",
"     48",
"    </a>",
"    ] and HIV-infected boys and girls aged 7 to 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/49\">",
"     49",
"    </a>",
"    ] suggest that it is both immunogenic and safe in these populations. However, efficacy data are not yet available. Studies in other immunocompromised populations are ongoing.",
"   </p>",
"   <p>",
"    HPV vaccine is recommended by the ACIP for persons who are immunocompromised as a result of infection, disease, or medications through age 26 years if they have not already received any or all vaccine doses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/27\">",
"     27",
"    </a>",
"    ]. It is not a live vaccine.",
"   </p>",
"   <p>",
"    Cervical cancer screening continues to play an important role in detection and treatment of cervical intraepithelial neoplasia (CIN) 2, 3, and cervical cancer in these high-risk females. Although there are no formal guidelines regarding screening for precancerous anal lesions, some specialists recommend anal cytologic screening for HIV-1-infected males and females. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link&amp;anchor=H10#H10\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Screening for AIN'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5968493\">",
"    <span class=\"h2\">",
"     Healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advisory Committee on Immunization Practices (ACIP) immunization schedule of 2012 indicates that healthcare personnel are not at increased risk of HPV infection due to occupational exposure; age-based recommendations noted above still apply [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVACCINATION ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP does not recommend serologic or HPV DNA testing prior to immunization in females or males [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     VACCINE DOSE AND ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967250\">",
"    <span class=\"h2\">",
"     Immunization schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunization schedules are slightly different for the quadrivalent and bivalent vaccines.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The quadrivalent vaccine (Gardasil) is administered in three doses at time zero, and at two and six months of follow-up.",
"     </li>",
"     <li>",
"      The bivalent vaccine (Cervarix) is administered in three doses at time zero, and at one and six months of follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967257\">",
"    <span class=\"h2\">",
"     Missed doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often do not follow-up for their immunizations on schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/51\">",
"     51",
"    </a>",
"    ]. In one study, vaccine efficacy of the quadrivalent vaccine remained high in persons who did not adhere to the recommended immunization schedule, including those who got fewer than three doses, suggesting some flexibility in the spacing of doses, although more data on the timing and number of doses and their impact on efficacy are needed before alternate dosing schedules can be adopted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/52\">",
"     52",
"    </a>",
"    ]. A clinical trial in Vietnam, which evaluated three alternative schedules with longer intervals between vaccine doses compared with standard dosing among 809 girls (aged 11 to 13 years), found equivalent HPV antibody titers one month after the final dose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/53\">",
"     53",
"    </a>",
"    ]. However, no data were presented on duration of response or efficacy against HPV infection or cervical disease.",
"   </p>",
"   <p>",
"    The Advisory Committee on Immunization Practices (ACIP) recommends that if the vaccination series is interrupted for any length of time, it can be resumed without restarting the series. The same formulation should be used to complete the series, if this information is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967264\">",
"    <span class=\"h2\">",
"     Postvaccination serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that the measurement of postvaccination antibody titers to monitor immunity is useful for determining who is protected against infection by the vaccine-targeted types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Duration of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV vaccines have shown excellent duration of protection for the time periods through which they have been studied. However, the duration of protection after immunization is unknown; to date, women have been protected during a mean follow-up time of 42 months after the first dose of quadrivalent HPV vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/54\">",
"     54",
"    </a>",
"    ]. The precise level of antibody needed for protection against infection is also unknown. Further data will become available in the future as female and male participants in vaccine studies are followed over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     VACCINE SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both vaccines use virus-like particles (VLPs), which mimic the viral capsid. VLPs do not contain genetic material and are produced in biologic systems, which have well-established safety records [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both vaccines appear to be safe in the context of clinical trials, although more is known about the safety profile of the quadrivalent vaccine than the bivalent vaccine due to availability of more postlicensure data, which are summarized below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Quadrivalent vaccine (Gardasil)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine safety data are now available from both registration trials and in postlicensure safety surveillance systems. Different types of information can be gleaned from these two processes. The advantage of safety reviews within the context of a clinical trial is that medical chart reviews of adverse events are usually more thorough and complete, whereas surveillance systems are voluntary and passive. However, postlicensure surveillance systems have the advantage of identifying a potentially serious side effect that may have been too rare to detect during prelicensure trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Prelicensure trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety profile of the quadrivalent vaccine was evaluated in diverse populations of females from resource-rich and resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/19,24\">",
"     19,24",
"    </a>",
"    ]. Mild injection site reactions were the most commonly observed adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The safety profile of quadrivalent vaccine in males was reported to be similar to that of studies in females [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Postlicensure data",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, adverse events following immunization are collected and analyzed within the Vaccine Adverse Event Reporting System (VAERS) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/58\">",
"     58",
"    </a>",
"    ]. Adverse events following HPV vaccine are compared with background rates following other immunizations. The following adverse events have been reported and compiled following administration of approximately 40 million doses of vaccine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From June 1, 2006 to September 2011, VAERS received 20,096 reports of adverse events following HPV immunization, 19,075 reports among females, and 569 reports for males. The vast majority (92 percent) were considered mild. The 8 percent considered to be serious included 72 deaths, of which 34 were confirmed. There was no unusual pattern or clustering to the deaths that would suggest that they were caused by the vaccine [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most of the adverse events rates were not greater than those reported with other vaccines, with the exception of syncope and venous thromboembolic events, as detailed in a 2008 report. Among the 1896 syncopal reports, 15 percent resulted in a fall or injury. Among the 31 patients with thromboembolism, 28 (90 percent) had a known risk factor (ie, estrogen-containing birth control pills or a family history of clotting disorder). There were 4 deaths reported among the 19 pulmonary embolism cases. Venous thromboembolism (VTE) was the only adverse event to meet the CDC screening criteria for \"signal detection\" and will continue to be closely monitored [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no increased risk of Guillain-Barr&eacute; Syndrome compared with other vaccines in similar age groups [",
"      <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anaphylaxis has also been reported following administration of the quadrivalent vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. In a mass school-based national vaccination program in Australia, the incidence of anaphylaxis was 2.6 per 100,000 doses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/60\">",
"     60",
"    </a>",
"    ]. However, some of those cases were subsequently thought not to have represented anaphylaxis and other studies from Australia did not confirm this high rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In the VAERS surveillance system, only 10 cases met predefined criteria for anaphylaxis; the overall risk ratio was 0.1 case per 100,000 doses distributed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies similarly observed that the quadrivalent vaccine is generally safe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/38,63\">",
"     38,63",
"    </a>",
"    ]. In a study of adverse events following over 600,000 quadrivalent vaccine doses administered to females in seven large managed care organizations, there were no increases in the prespecified events of Guillain-Barr&eacute; Syndrome (GBS), stroke, venous thromboembolism (VTE), appendicitis, seizures, syncope, allergic reactions, and anaphylaxis associated with vaccine receipt [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/38\">",
"     38",
"    </a>",
"    ]. Although there was a nonsignificant increase in the risk of VTE following vaccination among females aged 9 to 17 years, individual review of the eight potential VTE cases revealed that only five met the standard case definition and all had other known risk factors for VTE (eg, oral contraceptive use, coagulation disorders, smoking, obesity or prolonged hospitalization). In an industry-sponsored study of almost 190,000 females in a large healthcare system who received at least one vaccine dose, emergency department visits or hospitalizations were higher during the postvaccine period compared with a subsequent control period for 10 of 265 diagnostic categories evaluated, including viral, bacterial, and skin infections and congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/63\">",
"     63",
"    </a>",
"    ]. An independent safety committee concluded that same-day syncopal events (OR 6, 95% CI 3.9-9.2) and local skin infections within two weeks of vaccination (OR 1.8, 95% CI 1.3-2.4) were the only adverse events likely associated with vaccine administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967291\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postlicensure safety profile presented after exhaustive review by experts at the CDC and FDA was broadly consistent with safety data from prelicensure trials, with the exception of syncope and venous thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/58\">",
"     58",
"    </a>",
"    ]. The incidence of syncope among adolescents has increased with the introduction of other routine immunizations as well, such as meningococcal vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/58,64\">",
"     58,64",
"    </a>",
"    ]. Ongoing evaluation of HPV vaccine safety by CDC and FDA continues to be reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ACIP recommends a routine 15-minute waiting period following vaccination so that the patient may continue in a sitting or supine position as needed; this may decrease the risk of syncope with subsequent injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bivalent vaccine (Cervarix)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase III, multinational prospective, double-blind, placebo-controlled trial of more than 18,000 females aged 15 to 25 years, the vaccine was well tolerated and there were no differences in serious adverse events between vaccine and placebo recipients. Because of low uptake of Cervarix in the US as of September 2011, only sparse postlicensure data are available. As of September 2011, there have been 52 VAERS reports of adverse events following administration of bivalent vaccine and the majority of these adverse events (98 percent) were considered nonserious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1772308\">",
"    <span class=\"h2\">",
"     Behavioral impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surveys of parents found a concern for sexual disinhibition in adolescent girls following HPV vaccine receipt, particularly among older and ethnic minority parents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Studies have not supported an increase in risky sexual behavior following vaccination. In a retrospective study of preteenage girls enrolled in a large healthcare system, the combined incidence of pregnancy testing, chlamydia testing, and contraception counseling was determined among those girls who did (n = 493) and did not (n = 905) receive at least one HPV vaccine dose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/67\">",
"     67",
"    </a>",
"    ]. After adjustment for baseline healthcare utilization, race, and socioeconomic status, HPV vaccination was not associated with an increased rate of these sexual activity-related outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     WHERE TO REPORT ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional data on the Vaccine Adverse Event Reporting System are available on the web [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/59\">",
"     59",
"    </a>",
"    ]. Instructions for reporting adverse events to the Vaccine Adverse Event Reporting System are available at",
"    <a class=\"external\" href=\"file://www.vaers.hhs.gov/\">",
"     www.vaers.hhs.gov",
"    </a>",
"    or by calling 800-822-7967 in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF CANCER SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967530\">",
"    <span class=\"h2\">",
"     Cervical screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer screening with cervical cytology (ie, Papanicolaou test) has reduced the incidence and mortality of cervical cancer by more than 70 percent over the past six decades [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/68\">",
"     68",
"    </a>",
"    ]. Cervical cancer screening continues to be of great importance since HPV immunization will not prevent approximately 25 to 30 percent of cervical cancers in HPV-na&iuml;ve females and does not protect females already infected with carcinogenic HPV types against the development of cancer.",
"   </p>",
"   <p>",
"    Screening for cervical cancer is recommended for all females beginning at age 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/69\">",
"     69",
"    </a>",
"    ]. A preventive healthcare visit is an opportune time to discuss and offer HPV vaccination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cervical screening depending on the age of the woman [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/31\">",
"     31",
"    </a>",
"    ]. The recommended modality and interval between screenings depends on the age of the patient, risk factors for cervical cancer (eg, a history of diethylstilbestrol (DES) exposure in utero, HIV infection, other immunosuppression), and results of prior screening tests. Detailed information regarding screening for cervical cancer is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5967545\">",
"    <span class=\"h2\">",
"     Anal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no formal guidelines regarding screening for precancerous anal lesions, some specialists recommend anal cytologic screening for HIV-1-infected males and females. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link&amp;anchor=H10#H10\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Screening for AIN'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     COST EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mathematical models have examined the cost effectiveness of HPV vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. One study suggested that vaccination of the entire United States population of 12-year-old girls would annually prevent more than 200,000 HPV infections, 100,000 abnormal cervical cytology examinations, and 3300 cases of cervical cancer if cervical cancer screening continued as currently recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccination becomes increasingly less cost effective with increasing age. Assuming that HPV vaccine provides lifelong immunity, the cost-effectiveness ratio is $43,600 per quality-adjusted life-year (QALY) gained when vaccinating 12-year-old girls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/74\">",
"     74",
"    </a>",
"    ]. However, in one analysis the cost of extending immunizations up to the age of 26 years was $152,700 per QALY [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/74\">",
"     74",
"    </a>",
"    ]. As in all cost-effectiveness studies, interpretation of these findings is limited by uncertainty and multiple assumptions made in the models.",
"   </p>",
"   <p>",
"    In various models, vaccinating both males and females is predicted to be more beneficial in reducing HPV infection and disease than by vaccinating only females, but at a higher cost than vaccinating females alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. However, models of cost effectiveness are limited by uncertainty regarding major issues such as duration of protection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/77\">",
"     77",
"    </a>",
"    ], the effect of herd immunity, level of vaccine uptake among girls and females, and the prevalence of vaccine-specific HPV types circulating in age-specific populations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/17/19738/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"       \"Patient information: Human papillomavirus (HPV) vaccine (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       \"Patient information: Genital warts (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=see_link\">",
"       \"Patient information: Pap tests (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"       \"Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"       \"Patient information: Genital warts in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"       \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent viral infection with carcinogenic HPV types causes virtually all cancer of the cervix and most cases of anal cancer. The carcinogenic types of HPV 16 and HPV 18, which are targeted by the current HPV vaccines, cause approximately 70 percent of all cervical cancers worldwide and 72 percent of anal cancers. HPV 6 and HPV 11 cause approximately 90 percent of genital warts. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The quadrivalent vaccine (Gardasil) includes HPV types 6, 11, 16, and 18, whereas the bivalent vaccine (Cervarix) includes HPV types 16 and 18. (See",
"      <a class=\"local\" href=\"#H5967752\">",
"       'Available vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HPV immunization is most effective among individuals who have not yet been infected with HPV (eg, before sexual debut). (See",
"      <a class=\"local\" href=\"#H4761822\">",
"       'Timing of immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multicenter, double-blind, placebo-controlled trials have demonstrated efficacy of both quadrivalent and bivalent HPV vaccines against incident and persistent cervical HPV infection due to vaccine types and the development of cervical intraepithelial neoplasia. Quadrivalent HPV vaccine also has demonstrated high efficacy against vaccine type-associated vaginal and vulvar intraepithelial neoplasia in addition to genital warts associated with HPV 6 and HPV 11. The efficacy of either HPV vaccine for the prevention of anal intraepithelial neoplasia has not been studied in females. (See",
"      <a class=\"local\" href=\"#H5967957\">",
"       'Efficacy and immunogenicity in females'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend HPV immunization of females, as advised by multiple expert panels (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Routine immunization should be offered to girls 11 to 12 years of age, but can be administered as early as nine years. Catch-up vaccination should be offered for females aged 13 to 26 years who have",
"      <strong>",
"      </strong>",
"      not been previously vaccinated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommendations for HPV immunization in females'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quadrivalent HPV vaccine is effective in preventing genital warts in young males and anal intraepithelial neoplasia among men who have sex with men (MSM). There are no data on the efficacy of bivalent vaccine to prevent anal intraepithelial neoplasia in males. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Efficacy and immunogenicity in males'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of quadrivalent HPV vaccine in males, as advised by expert panels (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Routine immunization should be offered to boys aged 11 to 12, but can be administered as early as nine years of age. Catch-up vaccination should be offered for males between the ages of 13 to 21 who have not been previously vaccinated. For MSM, catch-up vaccination should be offered up to age 26. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Efficacy and immunogenicity in males'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although neither HPV vaccine contains live virus, use in pregnancy is not recommended because of limited data on safety. (See",
"      <a class=\"local\" href=\"#H5967665\">",
"       'Pregnant females'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic testing or HPV DNA testing is not required prior to immunization. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prevaccination assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest immunization of immunocompromised or immunosuppressed individuals with the HPV vaccine following the same guidelines as for immunocompetent patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Catch-up vaccination among these patients is recommended up to age 26 years. Cytologic screening continues to play an important role in detection and treatment of cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ and prevention of cervical cancer in these high-risk patients. (See",
"      <a class=\"local\" href=\"#H5967614\">",
"       'Immunization in special patient populations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"       \"Screening for cervical cancer: Rationale and recommendations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"       \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The quadrivalent vaccine (Gardasil) is administered in three doses at time zero, and at two and six months of follow-up. The bivalent vaccine (Cervarix) is administered in three doses at time zero, and at one and six months of follow-up. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Vaccine dose and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In prelicensure clinical trials and postlicensure monitoring, vaccines have been demonstrated to be generally safe. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Vaccine safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical cancer screening is recommended for any woman 21 years of age or older. Clinicians should be aware that HPV immunization is not effective in clearing cytologically evident disease or HPV infection that is already present. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Importance of cancer screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"       \"Screening for cervical cancer: Rationale and recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/1\">",
"      Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/2\">",
"      Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5:F12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/3\">",
"      Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004; 191:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/4\">",
"      De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/5\">",
"      Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/6\">",
"      Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/7\">",
"      Robinson D, Coupland V, M&oslash;ller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009; 100:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/8\">",
"      Daling JR, Weiss NS, Klopfenstein LL, et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982; 247:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/9\">",
"      Melbye M, Cot&eacute; TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994; 343:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/10\">",
"      Goedert JJ, Cot&eacute; TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/11\">",
"      Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/12\">",
"      Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/13\">",
"      Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/14\">",
"      A human papillomavirus vaccine. Med Lett Drugs Ther 2006; 48:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/15\">",
"      Cervarix--a second HPV vaccine. Med Lett Drugs Ther 2010; 52:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/16\">",
"      Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24:5571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/17\">",
"      Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/18\">",
"      GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/19\">",
"      Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928.",
"     </a>",
"    </li>",
"    <li>",
"     Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant Vaccines and Related Biological Products Advisory Committee (VRBPAC) Briefing Document, September 9, 2009. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM181371.pdf (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/21\">",
"      Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/22\">",
"      Lin SW, Ghosh A, Porras C, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One 2013; 8:e53067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/23\">",
"      Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/24\">",
"      FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/25\">",
"      Paavonen J, Naud P, Salmer&oacute;n J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/26\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/28\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann Intern Med 2010; 152:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/29\">",
"      Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/30\">",
"      Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/31\">",
"      Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/32\">",
"      Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/33\">",
"      Pet&auml;j&auml; T, Ker&auml;nen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009; 44:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/34\">",
"      Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/35\">",
"      Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/37\">",
"      Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/38\">",
"      Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29:8279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/39\">",
"      Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/40\">",
"      Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29:8443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/41\">",
"      Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults - United States, 2011. MMWR Morb Mortal Wkly Rep 2013; 62:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/42\">",
"      Castle PE, Scarinci I. Should HPV vaccine be given to men? BMJ 2009; 339:b4127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/43\">",
"      Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 Suppl 3:S3/11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/44\">",
"      Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113:3036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/45\">",
"      Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007; 16:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/46\">",
"      Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006; 163:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/47\">",
"      American College of Obstetricians and Gynecologists Committee on Health Care for Undeserved Women. ACOG Committee Opinion No. 343: psychosocial risk factors: perinatal screening and intervention. Obstet Gynecol 2006; 108:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/48\">",
"      Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/49\">",
"      Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/50\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2012. Ann Intern Med 2012; 156:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/51\">",
"      Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/52\">",
"      Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/53\">",
"      Neuzil KM, Canh do G, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011; 305:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/54\">",
"      Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/55\">",
"      Frazer IH, Cox JT, Mayeaux EJ Jr, et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr Infect Dis J 2006; 25:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/56\">",
"      Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/57\">",
"      Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/58\">",
"      Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccinesafety/Vaccines/HPV/gardasil.html (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/60\">",
"      Brotherton JM, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008; 179:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/61\">",
"      Douglas RJ. Anaphylaxis following quadrivalent human papillomavirus vaccination - even safer than it appears. CMAJ 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/62\">",
"      Kang LW, Crawford N, Tang ML, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 2008; 337:a2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/63\">",
"      Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012; 166:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/65\">",
"      Schuler CL, Reiter PL, Smith JS, Brewer NT. Human papillomavirus vaccine and behavioural disinhibition. Sex Transm Infect 2011; 87:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/66\">",
"      Marlow LA, Forster AS, Wardle J, Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J Adolesc Health 2009; 44:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/67\">",
"      Bednarczyk RA, Davis R, Ault K, et al. Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics 2012; 130:798.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Cancer Facts and Figures 2004. www.cancer.org/downloads/STT/CAFF_FinalPWSecured.pdf (Accessed on March 27, 2006).",
"    </li>",
"    <li>",
"     Clinical management guidelines for the Obstetrician-Gynecologists. Cervical cytology screening. ACOG Practice Bulletin 2009;109. (Replaces Practice Bulletin Number 45, August 2003 and Committee Opinion Number 431, May 2009)",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/70\">",
"      Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/71\">",
"      Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/72\">",
"      Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781.",
"     </a>",
"    </li>",
"    <li>",
"     Chesson HW, et al. Cost effectiveness models of HPV vaccines. May 9, 2006 - 2006 National STD Prevention Conference.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/74\">",
"      Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/75\">",
"      Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/76\">",
"      Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/77\">",
"      Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/17/19738/abstract/78\">",
"      Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8325 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19738=[""].join("\n");
var outline_f19_17_19738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16844157\">",
"      HPV-related disease in females",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5967919\">",
"      - Cervical cancer and precursor lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16844243\">",
"      - Vulvar and vaginal cancer and precursor lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16844286\">",
"      HPV-related disease in females and males",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2351179\">",
"      - Anal cancer and precursor lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2351186\">",
"      - Genital warts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16844306\">",
"      HPV-related diseases in males",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16844314\">",
"      - Penile cancer and precursor lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5967752\">",
"      AVAILABLE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5967957\">",
"      EFFICACY AND IMMUNOGENICITY IN FEMALES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16661848\">",
"      Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12598503\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Quadrivalent HPV vaccine (Gardasil)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bivalent HPV vaccine (Cervarix)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RECOMMENDATIONS FOR HPV IMMUNIZATION IN FEMALES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4761822\">",
"      Timing of immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5968335\">",
"      Expert guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Advisory Committee on Immunization Practices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9255720\">",
"      - Pediatric, gynecologic, and family practice societies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - American Cancer Society",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - World Health Organization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EFFICACY AND IMMUNOGENICITY IN MALES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16844411\">",
"      Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16844442\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93840009\">",
"      RECOMMENDATIONS FOR HPV IMMUNIZATION IN MALES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4762066\">",
"      Timing of immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967227\">",
"      Expert guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967234\">",
"      Controversies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5967614\">",
"      IMMUNIZATION IN SPECIAL PATIENT POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967665\">",
"      Pregnant females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5968479\">",
"      Immunization in females with preexisting cervical abnormalities or genital warts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5968486\">",
"      Immunosuppressed or immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5968493\">",
"      Healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVACCINATION ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      VACCINE DOSE AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967250\">",
"      Immunization schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967257\">",
"      Missed doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967264\">",
"      Postvaccination serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Duration of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      VACCINE SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Quadrivalent vaccine (Gardasil)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Prelicensure trial data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Postlicensure data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5967291\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bivalent vaccine (Cervarix)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1772308\">",
"      Behavioral impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      WHERE TO REPORT ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      IMPORTANCE OF CANCER SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967530\">",
"      Cervical screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5967545\">",
"      Anal screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      COST EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12761?source=related_link\">",
"      Classification and epidemiology of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=related_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=related_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=related_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26229?source=related_link\">",
"      The life cycle, natural history, and immunology of human papillomaviruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_17_19739="Uses of pancreatic stents";
var content_f19_17_19739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Settings in which pancreatic stents are being used",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pancreatic ductal strictures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unextractable pancreatic ductal stones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pancreatic pseudocysts and duct disruptions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Transpapillary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Transmural (duodenal/gastric)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Papillary stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Minor (pancreas divisum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Major",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevention of procedure-induced pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Guide for sphincterotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Biliary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreatic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19739=[""].join("\n");
var outline_f19_17_19739=null;
var title_f19_17_19740="WHO classification lung cancer 2004";
var content_f19_17_19740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2004 WHO classification of invasive malignant epithelial lung tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variants: papillary, clear cell, small cell, basaloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Small cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variant: combined small cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenocarcinoma, mixed subtype",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acinar adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papillary adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bronchioloalveolar carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Variants: nonmucinous, mucinous, mixed nonmucinous and mucinous or indeterminate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Solid adenocarcinoma with mucin production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Variants: fetal adenocarcinoma, mucinous (\"colloid\") carcinoma, mucinous cystadenocarcinoma, signet ring adenocarcinoma, clear cell adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Large cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variants: large cell neuroendocrine carcinoma, combined large cell neuroendocrine carcinoma, basaloid carcinoma, lymphoepithelioma-like carcinoma, clear cell carcinoma, large cell carcinoma with rhaboid phenotype",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adenosquamous carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sarcomatoid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variants: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, pulmonary blastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Carcinoid tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variants: typical carcinoid, atypical carcinoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Salivary gland tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variants: mucoepidermoid carcinoma, adenoid cystic carcinoma, epithelial-myoepithelial carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Travis, WD, Brambilla, E, Muller-Hermlink, HK, Harris, CC (eds). World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press. Lyon 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19740=[""].join("\n");
var outline_f19_17_19740=null;
var title_f19_17_19741="Anticholinergics end of life";
var content_f19_17_19741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F81557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F81557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticholinergic therapy for drying secretions* at the end of life",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;Agents&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;Adult dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycopyrrolate (glycopyrronium)",
"       </td>",
"       <td>",
"        <p>",
"         0.2 mg SC every&nbsp;four to&nbsp;six hours",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         0.2 mg SC once; followed after 30 minutes by SC or IV&nbsp;continuous infusion of 0.6 to 1.2 mg/day",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         0.1 mg sublingually (SL) every&nbsp;six hours as needed (use commercially available or compounded oral liquid)",
"         <sup>",
"          [2]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scopolamine (hyoscine",
"        <sup>",
"         &bull;",
"        </sup>",
"        ) base transdermal",
"       </td>",
"       <td>",
"        Apply&nbsp;one patch every 72 hours (1.5 mg patch releases &asymp;1 mg scopolamine base over 72 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Scopolamine (hyoscine",
"         <sup>",
"          &bull;",
"         </sup>",
"         ) BUTYLbromide",
"        </p>",
"        <p>",
"         (",
"         <strong>",
"          not",
"         </strong>",
"         available in US)",
"        </p>",
"        <p>",
"         SEE NOTE",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         20&nbsp;mg SC every four to six hours",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         20 mg SC once; followed after 30 minutes by SC or IV continuous&nbsp;infusion of 20 to 60 mg per day",
"         <sup>",
"          [3]&Delta;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Scopolamine&nbsp;(hyoscine",
"         <sup>",
"          &bull;",
"         </sup>",
"         ) HYDRObromide",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         SEE NOTE",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.3 mg PO or SL every&nbsp;four to&nbsp;six hours (PO/SL",
"         <strong>",
"          not",
"         </strong>",
"         available in US)",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         0.4 to 0.6 mg SC every&nbsp;four to&nbsp;eight hours",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         0.4 mg&nbsp;SC once; followed after 30 minutes by a SC or IV infusion of&nbsp;1.2&nbsp;to 2 mg per day",
"         <sup>",
"          [1,3]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atropine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         0.4 to 0.6 mg SC every&nbsp;four to&nbsp;six hours",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         One&nbsp;to&nbsp;two drops of&nbsp;1% ophthalmic solution&nbsp;(0.5 mg/drop) administered SL every&nbsp;two to&nbsp;four hours",
"         <sup>",
"          [4]&loz;",
"         </sup>",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         0.4 mg SC once; followed after 30 minutes by a SC infusion of 1.2 to 2 mg per day",
"         <sup>",
"          [2]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    IMPORTANT NOTE: Doses of scopolamine (hyoscine) BUTYLbromide are&nbsp;NOT equivalent to&nbsp;scopolamine (hyoscine) HYDRObromide on a mg basis and may not be interchanged.&nbsp;Preparations not available in the US are widely available in other countries.",
"    <br>",
"     SC: subcutaneous; IV: intravenous; PO: oral; SL: sublingual",
"     <div class=\"footnotes\">",
"      * Also known as \"death rattle\".",
"      <br>",
"       &bull; Hyoscine is&nbsp;an international generic&nbsp;name.&nbsp;Scopolamine is the US generic name.",
"       <br>",
"        &Delta;&nbsp;Larger subcutaneous&nbsp;continuous infusion&nbsp;doses of scopolamine (hyoscine) BUTYLbromide up to 120 mg per day may be needed.",
"        <sup>",
"         [2]",
"        </sup>",
"        &nbsp;Adjust dose&nbsp;depending upon response. Repeat SC dose if needed.",
"        <sup>",
"         [3]",
"         <br/>",
"        </sup>",
"        &loz; Scopoloamine (hyoscine) HYDRObromide penetrates central nervous system;&nbsp;it&nbsp;is sedating and can cause or worsen&nbsp;delirium.",
"        <sup>",
"         [2]",
"        </sup>",
"        <br>",
"         &sect; Atropine is a 2nd line choice. Disadvantages include&nbsp;risk of&nbsp;central nervous system&nbsp;toxicity&nbsp;(eg, hallucinations) and/or cardiotoxicity.&nbsp;Sublingual administration of ipratropium nasal solution (two sprays) may&nbsp;be a&nbsp;useful&nbsp;alternative.",
"         <sup>",
"          [4]",
"         </sup>",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"      [1] Hugel H, Ellershaw J, Gambles M. Respiratory Tract Secretions in the Dying Patient: A Comparison between Glycopyrronium and Hyoscine Hydrobromide. J Palliat Med 2006; 9:279.",
"      <br>",
"       [2] Twycross R, Wilcock A (Eds). Hospice and palliative care formulary, 4th ed, Palliativedrugs.com Ltd. &copy;2012. p.637.",
"       <br>",
"        [3] Bennett M, Lucas V, Brennan M, et al. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 2002; 16:369.",
"        <br>",
"         [4] Kintzel PE, Chase SL, Thomas W, et al. Anticholinergic medications for managing noisy respirations in adult hospice patients. Am J Health Syst Pharm 2009; 66:458.",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19741=[""].join("\n");
var outline_f19_17_19741=null;
var title_f19_17_19742="Family reduviidae";
var content_f19_17_19742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Classification of insects in the family Reduviidae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 204px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moffitt, JE, Venarske, D, Goddard, J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122. Copyright &copy; 2003 American College of Allergy, Asthma, and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19742=[""].join("\n");
var outline_f19_17_19742=null;
var title_f19_17_19743="Accessory hepatic ducts";
var content_f19_17_19743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Accessory hepatic ducts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_17_19743=[""].join("\n");
var outline_f19_17_19743=null;
